<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antipsychotic combinations for schizophrenia - Ortiz‐Orendain, J - 2017 | Cochrane Library</title> <meta content="Antipsychotic combinations for schizophrenia - Ortiz‐Orendain, J - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009005.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antipsychotic combinations for schizophrenia - Ortiz‐Orendain, J - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009005.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009005.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antipsychotic combinations for schizophrenia" name="citation_title"/> <meta content="Javier Ortiz‐Orendain" name="citation_author"/> <meta content="University of Guadalajara" name="citation_author_institution"/> <meta content="jaortzor@gmail.com" name="citation_author_email"/> <meta content="Santiago Castiello‐de Obeso" name="citation_author"/> <meta content="University of Guadalajara" name="citation_author_institution"/> <meta content="Luis Enrique Colunga‐Lozano" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Yue Hu" name="citation_author"/> <meta content="Tianjin University of Traditional Chinese Medicine" name="citation_author_institution"/> <meta content="Nicola Maayan" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009005.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009005.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009005.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009005.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*therapeutic use]; Clozapine [therapeutic use]; Drug Therapy, Combination; Patient Dropouts [statistics &amp; numerical data]; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia [*drug therapy]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009005.pub2&amp;doi=10.1002/14651858.CD009005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009005\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009005\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009005.pub2",title:"Antipsychotic combinations for schizophrenia",firstPublishedDate:"Jun 28, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009005.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009005.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009005.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009005.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009005.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009005.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009005.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009005.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009005.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009005.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14529 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009005.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0218"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0111"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-sec-0204"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/appendices#CD009005-sec-0229"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/table_n/CD009005StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/table_n/CD009005StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antipsychotic combinations for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#CD009005-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Javier Ortiz‐Orendain</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#CD009005-cr-0003">Santiago Castiello‐de Obeso</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#CD009005-cr-0004">Luis Enrique Colunga‐Lozano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#CD009005-cr-0005">Yue Hu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#CD009005-cr-0006">Nicola Maayan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information#CD009005-cr-0007">Clive E Adams</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information/en#CD009005-sec-0257">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009005.pub2">https://doi.org/10.1002/14651858.CD009005.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009005-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009005-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009005-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009005-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009005-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009005-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009005-abs-0001" lang="en"> <section id="CD009005-sec-0001"> <h3 class="title" id="CD009005-sec-0001">Background</h3> <p>Many people with schizophrenia do not achieve a satisfactory treatment response with their initial antipsychotic drug treatment. Sometimes a second antipsychotic, in combination with the first, is used in these situations. </p> </section> <section id="CD009005-sec-0002"> <h3 class="title" id="CD009005-sec-0002">Objectives</h3> <p>To examine whether:</p> <p>1. treatment with antipsychotic combinations is effective for schizophrenia; and<br/> 2. treatment with antipsychotic combinations is safe for the same illness. </p> </section> <section id="CD009005-sec-0003"> <h3 class="title" id="CD009005-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's register which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There are no language, time, document type, or publication status limitations for inclusion of records in the register. We ran searches in September 2010, August 2012 and January 2016. We checked for additional trials in the reference lists of included trials. </p> </section> <section id="CD009005-sec-0004"> <h3 class="title" id="CD009005-sec-0004">Selection criteria</h3> <p>We included all randomised and quasi‐randomised controlled trials comparing antipsychotic combinations with antipsychotic monotherapy for the treatment of schizophrenia and/or schizophrenia‐like psychoses. </p> </section> <section id="CD009005-sec-0005"> <h3 class="title" id="CD009005-sec-0005">Data collection and analysis</h3> <p>We independently extracted data from the included studies. We analysed dichotomous data using risk ratios (RR) and the 95% confidence intervals (CI). We analysed continuous data using mean difference (MD) with a 95% CIs. For the meta‐analysis we used a random‐effects model. We used GRADE to complete a 'Summary of findings' table and assessed risk of bias for included studies. </p> </section> <section id="CD009005-sec-0006"> <h3 class="title" id="CD009005-sec-0006">Main results</h3> <p>Sixty‐two studies are included in the review, 31 of these compared clozapine monotherapy with clozapine combination. We considered the risk of bias in the included studies to be moderate to high. The majority of trials had unclear allocation concealment, method of randomisation and blinding, and were not free of selective reporting. </p> <p>There is some limited evidence that combination therapy may be superior to monotherapy in reducing the risk of no clinical response (RR 0.73 CI 0.64 to 0.83; participants = 2398; studies = 29; <i>very low‐quality evidence</i> ), subgroup analyses show that the positive result was due to the studies with clozapine in both the monotherapy and combination groups (RR 0.66 CI 0.53 to 0.83; participants = 1127; studies = 17) and typical in both groups (RR 0.64 CI 0.49 to 0.84; participants = 597; studies = 5). The subgroup with atypical antipsychotics in both groups did not showed a difference between the two interventions (RR 0.95 CI 0.83 to 1.09; participants = 674; studies = 7). Three studies provided data regarding relapse, the pooled data showed high heterogeneity (I² = 82%) and therefore the results were not pooled. Two studies showed no difference between the interventions and one study showed that antipsychotics combination might decrease the risk of relapse. A combination of antipsychotics was not superior or inferior to antipsychotic monotherapy in reducing the number of participants discontinuing treatment early (RR 0.90 CI 0.76 to 1.07; participants = 3137; studies = 43, <i>low‐quality evidence</i> ). No difference was found between treatment groups in the number of participants hospitalised (RR 0.96 CI 0.36 to 2.55; participants = 202; studies = 3, <i>very low‐quality evidence</i> ). We did not find evidence of a difference between treatment groups in serious adverse events or those requiring discontinuation (RR 1.05 CI 0.65 to 1.69; participants = 2398; studies = 30, <i>very low‐quality evidence</i>). There is a lack of evidence on clinically important change in quality of life, with only four studies reporting average endpoint or change data for this outcome on three different scales, none of which showed a difference between treatment groups. </p> </section> <section id="CD009005-sec-0007"> <h3 class="title" id="CD009005-sec-0007">Authors' conclusions</h3> <p>Currently, most evidence regarding the use of antipsychotic combinations comes from short‐term trials, limiting the assessment of long‐term efficacy and safety. We found very low‐quality evidence that a combination of antipsychotics may improve the clinical response. We also found very low‐quality evidence that a combination of antipsychotics may make no difference at preventing participants from leaving the study early, preventing relapse and/or causing more serious adverse events than monotherapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009005-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009005-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009005-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009005-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009005-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009005-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009005-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009005-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009005-abs-0005" lang="en"> <h3>Combining antipsychotic medication for the treatment of schizophrenia</h3> <p><b>Background</b> </p> <p>Antipsychotic medication was introduced in the 1950s to reduce or alleviate the symptoms of schizophrenia, such as the psychotic states of hearing voices, visual hallucinations and strange thoughts such as paranoia (feeling singled‐out or put upon by others). Medication for mental illness also helped to establish care in the community, because people could take medication in their homes or by regularly visiting the hospital. But this also led to new issues such as the effectiveness of different medication (taken alone or in combination) and compliance (the willingness of service users to take their medication without being supervised). </p> <p>The range of antipsychotic medication available is wide and their effectiveness can also vary from individual to individual. In addition, not all patients fully respond to a single antipsychotic, and in these situations, a combination of antipsychotics are often prescribed. The evidence for the benefits of taking one or more antipsychotics in combination is often unclear. There are also differing profiles of typical (first generation) and atypical (second generation) antipsychotics adding to a confusing array of terminology and dilemma of what is the best medication for service users. </p> <p><b>Searches</b> </p> <p>This review investigates the effects of different antipsychotic combinations compared with single antipsychotics for people with schizophrenia. Searches for randomised controlled trials have now been run by the Information Specialist of the Cochrane Schizophenia Group in 2010, 2012 and 2016. Sixty‐two trials, reporting useable data, are included in the review. </p> <p><b>Main results</b> </p> <p>The review of available evidence found that combinations of antipsychotics may be more effective in treating symptoms of schizophrenia compared with taking one antipsychotic. In particular, combination treatments that included clozapine and typical antipsychotic in both groups were found to be effective. Few studies reported on this central issue of relapse rates (service users becoming unwell again), but this was because most of the studies were of short length (whereas schizophrenia is a long‐term health problem that requires studies of an equally long duration). No real differences were found between combinations of antipsychotics and single antipsychotics for preventing relapse and roughly equal numbers of people discontinued their treatment. There was also no difference between combination therapy and monotherapy regarding hospital admission and/or occurrence of serious adverse events. Numbers leaving the studies early were similar. Clinically meaningful data for quality of life were not reported. </p> <p><b>Conclusions</b> </p> <p>These results show that there may be some clinical benefit for combination therapy in that more people receiving a combination of antipsychotic showed an improvement in symptoms. For other important outcomes such as relapse, hospitalisation, adverse events, discontinuing treatment or leaving the study early, no clear differences between the two treatment options were observed. However, these results are based on very low or low‐quality evidence and more research providing high‐quality evidence is needed before firm conclusions can be made. </p> <p>This plain language summary has been adapted from an original summary by Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness. Email: <a class="__cf_email__" data-cfemail="f092959ede97829189b082958498999e9bde9f8297" href="/cdn-cgi/l/email-protection">[email protected]</a> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009005-sec-0218" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009005-sec-0218"></div> <h3 class="title" id="CD009005-sec-0219">Implications for practice</h3> <section id="CD009005-sec-0219"> <section id="CD009005-sec-0220"> <h5 class="title">1. For people with schizophrenia</h5> <p>Currently, there is very low‐quality evidence that the use of antipsychotic combinations results in a clinical improvement when compared with monotherapy. There is no evidence that combination antipsychotic therapy does that much, either in terms of leaving the study early and/or adverse events. Quality of evidence is low and unique positive reactions to combinations of drugs do occur. All we can say is that combinations do not have a clear advantage over monotherapy from within the context of trials. </p> </section> <section id="CD009005-sec-0221"> <h5 class="title">2. For clinicians</h5> <p>As a clinician it is common to find a person on a combination of antipsychotics or to be tempted to add other drugs to an already established, but clearly inadequate antipsychotic regimen. This review does not preclude adding an additional antipsychotic, nor does this review suggest that discontinuation of one of the two combination antipsychotics is necessarily indicated. All should be done with caution due to lack of sufficient evidence. It would be beneficial if clinicians that face the clinical question addressed in this review, began to randomise their patients to contribute to the body of evidence. </p> </section> <section id="CD009005-sec-0222"> <h5 class="title">3. For policymakers</h5> <p>It would seem sensible that the fewer antipsychotics, the better ‐ but some people do seem to do well on combinations of antipsychotics and there is a risk of upsetting this group of people by stipulating that it is going against policy to have people on more than one antipsychotic. Furthermore, there is not good quality evidence for this stipulation. </p> </section> </section> <h3 class="title" id="CD009005-sec-0223">Implications for research</h3> <section id="CD009005-sec-0223"> <section id="CD009005-sec-0224"> <h5 class="title">1. General</h5> <p>Registration of trials before anyone is randomised would ensure that participants could be confident that people would know that the study had at least taken place. Unique study numbers would help researchers identify single studies from multiple publications and reduce the risk of duplicating the reporting of data. </p> <p>Compliance with <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> would help clarify methodology and many outcomes. Failure to do this results in both loss of data and confusion in the results. </p> </section> <section id="CD009005-sec-0225"> <h5 class="title">2. Specific</h5> <section id="CD009005-sec-0226"> <h6 class="title">2.1 Trials</h6> <p>It would be beneficial to people with schizophrenia if there was a long‐term (e.g. &gt; one year) trial comparing antipsychotics combination with monotherapy. The outcomes measured should include leaving the study early, clinical improvement, relapse, adverse events and quality of life, which is an important outcome that has been overlooked in most trials. We do realise that such a study is a considerable undertaking and that we have only reviewed others' work in this area. However, that does give a perspective and we have suggested a design of study in <a href="#CD009005-tbl-0003">Table 2</a>.The fact that the last clinical trials which used a combination of typical antipsychotics was more than 30 years ago, is concerning as this review suggests the use of these drugs might have a place in the care of the patients with schizophrenia. Overlooking the typical antipsychotics in the design of new trials could potentially mislead the consumers to use more atypical antipsychotics. </p> <div class="table" id="CD009005-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation</b> : randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> <b>Blindness</b> : double ‐ described and tested.<br/> <b>Duration</b>: 12 months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diagnosis:</b> schizophrenia (operational criteria).<br/> <b>N</b> = 600. *<br/> <b>Age:</b> any.<br/> <b>Gender:</b> both.<br/> <b>History:</b> any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Antipsychotic combination. N = 300.<br/> 2. Antipsychotic of choice. N = 300. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD009005-list-0004"> <li> <p>Global impression: CGI**, relapse, clinical improvement.</p> </li> <li> <p>Leaving study early (any reason, adverse events, inefficacy).</p> </li> <li> <p>Service outcomes: hospitalised, time in hospital, attending out patient clinics.</p> </li> <li> <p>Adverse events: major and minor problems as perceived by participant and clinician.</p> </li> <li> <p>Employment, family satisfaction, patient satisfaction.</p> </li> <li> <p>Quality of life: simple binary rating.</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> ** Primary outcome. </p> <p>CGI ‐ Clinical Global Impression.</p> </div> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009005-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009005-sec-0029"></div> <div class="table" id="CD009005-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combinations of antipsychotic drugs compared to single antipsychotic drugs for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Combinations of antipsychotic drugs compared to single antipsychotic drugs for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> schizophrenia or related disorders<br/> <b>Setting:</b> outpatients and inpatients<br/> <b>Intervention:</b> combinations of antipsychotic drugs<br/> <b>Comparison:</b> single antipsychotic drugs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single antipsychotic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with combinations of antipsychotic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response: No clinically important response</p> <p>‐ as defined by each of the studies<br/> follow up: range 4 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/> (0.64 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2398<br/> (29 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>512 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>374 per 1,000<br/> (328 to 425) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Relapse ‐ as defined by each of the studies<br/> follow up: range 2 months to 36 </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>512<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Data were not pooled due to high heterogeneity (I<sup>2</sup> = 82%). Two studies showed no difference between the interventions and one study favoured antipsychotic combinations. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leaving the study early<br/> follow up: range 6 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.76 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3137<br/> (43 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 5 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1,000<br/> (139 to 195) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service utilisation: Hospital admission<br/> follow up: range 12 weeks to 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.36 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>202<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1,000<br/> (25 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service utilisation: Change in hospital status ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No studies provided data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: Serious event or requiring discontinuation<br/> follow up: range 6 weeks to 8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.65 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2398<br/> (30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 5 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1,000<br/> (31 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: QLS, SWN and SF‐36<br/> follow up: range 6 weeks to 16 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were not pooled, as they were presented in both change and endpoint data for 3 different scales. None of the scales showed a difference between the two groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias. </p> <p><sup>2</sup> Downgraded one level due to inconsistency. </p> <p><sup>3</sup> Although there is a concern about the timeframe to measure the outcome we decided not to downgrade due to overall quality assessment. </p> <p><sup>4</sup> Downgraded one level due to publication bias. </p> <p><sup>5</sup> Downgraded one level due to imprecision. </p> <p><sup>6</sup> Downgraded one level due to indirectness. </p> <p><sup>7</sup> Although there is a concern about the influence on industry we decided not to downgrade due to overall quality assessment. </p> <p><sup>8</sup> Downgraded two levels due to inconsistency. </p> <p>Please see Checklist to aid consistency and reproducibility of GRADE assessments <a href="./appendices#CD009005-sec-0230">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009005-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009005-sec-0030"></div> <section id="CD009005-sec-0031"> <h3 class="title" id="CD009005-sec-0031">Description of the condition</h3> <p>Schizophrenia is a chronic disorder with a lifetime prevalence of four per 1000 persons (<a href="./references#CD009005-bbs2-0180" title="McGrathJ , SahaS , WelhamJ . Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews2008;30(1):67‐76. [DOI: 10.1093/epirev/mxn001] ">McGrath 2008</a>). It is characterised by emotional, cognitive, and behavioural dysfunctions. In order to meet the diagnostic criteria of schizophrenia, patients require two or more positive, disorganised, or negative symptoms that persist for at least six months, with at least one of them being a positive symptom or disorganised speech (<a href="./references#CD009005-bbs2-0136" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐5. Washington, DC: American Psychiatric Publishing, 2013. [DOI: 10.1176/appi.books.9780890425596] ">APA 2013</a>). Positive symptoms include delusions (e.g. a false belief that is resistant to change, immune to contradictory evidence, and without correlation to the sociocultural background) and hallucinations (e.g. a sensory experience in the absence of external stimulus to the corresponding sensory organ). Negative symptoms are characterised by deficits in normal behaviour, which consist of five domains: blunted affect, alogia, asociality, anhedonia, and avolition (<a href="./references#CD009005-bbs2-0173" title="KirkpatrickB , FentonWS , CarpenterWT , MarderSR . The NIMH‐MATRICS consensus statement on negative symptom. Schizophrenia bulletin2006;32(2):214‐9. [DOI: 10.1093/schbul/sbj053] ">Kirkpatrick 2006</a>). </p> <p>Schizophrenia is difficult to treat and significantly burdens an individual's daily life. Despite the introduction of antipsychotics in the 1950s and the reintroduction of clozapine to the Western world, the mean recovery rate of schizophrenia is 13.5% (<a href="./references#CD009005-bbs2-0168" title="Jääskeläinen , JuolaP , HirvonenN , McGrathJ , SahaS , IsohanniM , et al. A systematic review and meta‐analysis of recovery in schizophrenia. Schizophrenia Bulletin2012;39(6):1296‐306. [DOI: 10.1093/schbul/sbs130] ">Jääskeläinen 2012</a>). In clinical practice, multiple augmentation strategies such as adding another antipsychotic, mood‐stabiliser, benzodiazepines, lithium, electroconvulsive therapy, or repetitive transcranial magnetic stimulation have been used for these patients in order to improve their clinical state, but the evidence for the use of these interventions is lacking (<a href="./references#CD009005-bbs2-0163" title="HasanA , FalkaiP , WobrockT , LiebermanJ , GlenthojB , GattazWF , et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry2012;13(5):318‐78. [DOI: 10.3109/15622975.2012.696143] ">Hasan 2012</a>). </p> </section> <section id="CD009005-sec-0032"> <h3 class="title" id="CD009005-sec-0032">Description of the intervention</h3> <p>Antipsychotic medications are the cornerstone for the treatment of schizophrenia. They were originally classified on the basis of their risk for the development of extrapyramidal side effects (EPS) as typical (e.g. chlorpromazine, haloperidol, fluphenazine) or atypical (e.g. clozapine, olanzapine, risperidone) if the risk for the development of EPS is low (<a href="./references#CD009005-bbs2-0160" title="GründerG , HippiusH , CarlssonA . The 'atypicality' of antipsychotics: a concept re‐examined and re‐defined. Nature Reviews Drug Discovery2009;8(3):197‐202. [DOI: 10.1038/nrd2806] ">Grunder 2009</a>). </p> <p>Antipsychotic polypharmacy/combination treatment, e.g. concurrent treatment with more than one antipsychotic medication, is a common strategy for the management of disturbed behaviour, poor response to antipsychotic monotherapy, or acute positive symptom exacerbation (<a href="./references#CD009005-bbs2-0187" title="PatonC , BarnesTR , CavanaghMR , TaylorD , LelliottP . High‐dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by prn prescribing. British Journal of Psychiatry2008;192(6):435‐9. [DOI: 10.1192/bjp.bp.107.042895] ">Paton 2008</a>). Concerning this practice, recommendations are varied. While some countries justify this practice (e.g. Finland, France, the UK), others recommend against it (e.g. Canada, Denmark, Spain), and many abstain from making any recommendation (<a href="./references#CD009005-bbs2-0156" title="GaebelW , WeinmannS , SartoriusN , RutzW , McIntyreJS . Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry2005;187(3):248‐55. [DOI: 10.1192/bjp.187.3.248] ">Gaebel 2005</a>). Regardless of the recommendations and lack of evidence, this practice has shown a trend towards increased use over time (<a href="./references#CD009005-bbs2-0158" title="GangulyR , KotzanJA , MillerLS , KennedyK , MartinBC . Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid‐eligible schizophrenia patients, 1998‐2000. Journal of Clinical Psychiatry2004;65(10):1377‐88. [DOI: 10.4088/JCP.v65n1013] ">Gangluy 2004</a>). It is estimated that 19.6% of patients with schizophrenia across the world receive antipsychotic polypharmacy/combination treatment (<a href="./references#CD009005-bbs2-0157" title="GallegoJA , BonettiJ , ZhangJ , KaneJM , CorrellCU . Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta‐regression of global and regional trends from the 1970s to 2009. Schizophrenia Research2012;138(1):18‐28. [DOI: 10.1016/j.schres.2012.03.018] ">Gallego 2009</a>). </p> </section> <section id="CD009005-sec-0033"> <h3 class="title" id="CD009005-sec-0033">How the intervention might work</h3> <p>Currently, there is not a current understanding of how the combination of antipsychotics might work. Plausible hypotheses include (<a href="./references#CD009005-bbs2-0154" title="FreudenreichO , GoffD . Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica2002;106:320‐30. [DOI: 10.1034/j.1600‐0447.2002.01331.x] ">Freudenreich 2002</a>): </p> <p> <ol id="CD009005-list-0001"> <li> <p>achieving optimal receptor occupancy;</p> </li> <li> <p>targeting different receptors with the added drug (<a href="./references#CD009005-bbs2-0169" title="KapurS , RemingtonG . Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry2001;50(11):873‐83. [DOI: 10.1016/S0006‐3223(01)01251‐3] ">Kapur 2001</a>); and </p> </li> <li> <p>reducing the dose‐related side‐effects by using lower doses of the two drugs.</p> </li> </ol> </p> </section> <section id="CD009005-sec-0034"> <h3 class="title" id="CD009005-sec-0034">Why it is important to do this review</h3> <p>A number of potential concerns regarding antipsychotic combinations have been identified. These include the possibility of unnecessarily high doses, an increased acute and/or chronic side‐effect burden, adverse pharmacodynamic and pharmacokinetic interactions, increased rates of non‐compliance, difficulties in determining cause and effect of multiple treatments, potential increased mortality, higher costs and poorly documented risks and benefits of this practice (<a href="./references#CD009005-bbs2-0143" title="CentorrinoF , FogartyKV , SaniG , SalvatoreP , CincottaSL , HennenJ , et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Human Psychopharmacology2005;20(7):485‐92. [DOI: 10.1002/hup.719] ">Centorrino 2005</a>; <a href="./references#CD009005-bbs2-0182" title="MeltzerHY , KostakogluAE . Combining antipsychotics: is there evidence for efficacy?. Psychiatric Times2000;17:25‐34. ">Meltzer 2000</a>; <a href="./references#CD009005-bbs2-0184" title="MisawaF , ShimizuK , FujiiY , MiyataR , KoshiishiF , KobayashiM , et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross‐sectional study. BMC Psychiatry2011;11(1):118. [DOI: 10.1186/1471‐244X‐11‐118] ">Misawa 2011</a>; <a href="./references#CD009005-bbs2-0188" title="RupnowMF , GreenspanA , GharabawiGM , Kosik‐GonzalezC , ZhuY , StahlSM . Incidence and costs of polypharmacy: data from a randomized, double‐blind, placebo‐controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Current Medical Research and Opinion2007;23(11):2815‐22. [DOI: 10.1185/030079907X233359] ">Rupnow 2007</a>; <a href="./references#CD009005-bbs2-0196" title="WaddingtonJL , YoussefHA , KinsellaA . Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10‐year prospective study. British Journal of Psychiatry1998;173:325‐9. ">Waddington 1998</a>; <a href="./references#CD009005-bbs2-0198" title='WeidenPJ , CaseyDE . "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia. Journal of Practical Psychiatry and Behavioral Health1999;5:229‐33. '>Weiden 1999</a>). In this review, we examine the evidence for the efficacy and safety of antipsychotic combinations in the treatment of schizophrenia and schizophrenia‐like psychoses. We are aware of the sister Cochrane review investigating the effects of different clozapine‐antipsychotic combinations (<a href="./references#CD009005-bbs2-0137" title="BarberS , OlotuU , CorsiM , CiprianiA . Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD006324.pub3; CD006324] ">Barber 2017</a>). However, this review is different in its scope as it investigates any combinations of antipsychotic therapy versus any antipsychotic monotherapy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009005-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009005-sec-0035"></div> <p>To examine whether:</p> <p> <ol id="CD009005-list-0002"> <li> <p>treatment with antipsychotic combinations is effective for schizophrenia; and</p> </li> <li> <p>treatment with antipsychotic combinations is safe for the same illness.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009005-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009005-sec-0036"></div> <section id="CD009005-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009005-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials (RCTs) and quasi‐RCTs. Where a trial was described as 'double‐blind' and it implied that the study was randomised and the demographic details of each group were similar, those trials were also included. After debate we decided to maintain the same inclusion criteria determined by previous authors to include quasi‐RCTs (see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). </p> </section> <section id="CD009005-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. </p> </section> <section id="CD009005-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD009005-sec-0041"> <h5 class="title">1. Treatment with more than one antipsychotic medication</h5> <p>Any dose and route of administration.</p> </section> <section id="CD009005-sec-0042"> <h5 class="title">2. Treatment with only one antipsychotic medication</h5> <p>Any dose and route of administration.</p> </section> </section> <section id="CD009005-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>We grouped outcomes into long term (over 26 weeks, A), medium term (13 to 26 weeks, B) and short term (up to 12 weeks, C). </p> <section id="CD009005-sec-0044"> <h5 class="title">Primary outcomes</h5> <section id="CD009005-sec-0045"> <h6 class="title">1. Clinical response</h6> <p>1.1 No clinically important response ‐ as defined by each of the studies</p> <p>1.2 Relapse ‐ as defined by each of the studies</p> </section> <section id="CD009005-sec-0046"> <h6 class="title">2. Leaving the study early</h6> </section> </section> <section id="CD009005-sec-0047"> <h5 class="title">Secondary outcomes</h5> <section id="CD009005-sec-0048"> <h6 class="title">1. Service utilisation</h6> <p>1.1 Hospital admission<br/> 1.2 Days in hospital<br/> 1.3 Change in hospital status </p> </section> <section id="CD009005-sec-0049"> <h6 class="title">2. Clinical response</h6> <p>2.1 No clinically important improvement of global state<br/> 2.2 Average score/change in global state<br/> 2.3 No clinically important improvement in mental state ‐ as defined by each of the studies<br/> 2.4 Average score/change in mental state<br/> 2.5 No clinically important response on positive symptoms ‐ as defined by each of the studies<br/> 2.6 Average score/change in positive symptoms<br/> 2.7 No clinically important response on negative symptoms ‐ as defined by each of the studies<br/> 2.8 Average score/change in negative symptoms<br/> 2.9 No clinically important response on aggression/agitation symptoms ‐ as defined by each of the studies<br/> 2.10 Average score/change in aggression/agitation symptoms </p> </section> <section id="CD009005-sec-0050"> <h6 class="title">3. Behaviour</h6> <p>3.1 General behaviour<br/> 3.2 Specific behaviours<br/> 3.2.1 Social functioning<br/> 3.2.2 Employment status during trial (employed / unemployed)<br/> 3.2.3 Occurrence of violent incidents (to self, others, or property)<br/> 3.2.4 Level of substance abuse </p> </section> <section id="CD009005-sec-0051"> <h6 class="title">4. Adverse events</h6> <p>4.1 Serious adverse events<br/> 4.2 Adverse events requiring hospitalisation<br/> 4.3 Specific adverse events<br/> 4.3.1 Allergic reactions<br/> 4.3.2 Blood dyscrasia such as agranulocytosis<br/> 4.3.3 Central nervous system (ataxia, nystagmus, drowsiness, fits, diplopia, tremor)<br/> 4.3.4 Death (suicide and non‐suicide deaths)<br/> 4.3.5 Endocrinological dysfunction (hyperprolactinaemia)<br/> 4.3.6 Weight gain<br/> 4.3.7 Movement disorders (extrapyramidal side effects (EPS)) </p> </section> <section id="CD009005-sec-0052"> <h6 class="title">5. Quality of life</h6> </section> <section id="CD009005-sec-0053"> <h6 class="title">6. Economic burden (cost of care)</h6> </section> <section id="CD009005-sec-0054"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD009005-bbs2-0190" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>), and used GRADE profiler (<a href="http://gradepro.org/" target="_blank">GRADEPRO</a>) to import data from RevMan 5 (<a href="http://www.tech.cochrane.org/revman" target="_blank">Review Manager</a>) in order to create a 'Summary of findings' table. This table provides outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision‐making. Also, we prepared an appendix (<a href="./appendices#CD009005-sec-0230">Appendix 1</a>) to help with the standardisation of the 'Summary of findings' table (please see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). We aimed to select the following main outcomes for inclusion in the 'Summary of findings' table. </p> <section id="CD009005-sec-0055"> <p><b>1. Clinical response</b></p> <p>1.1 No clinically important response ‐ as defined by each of the studies</p> <p>1.2 Relapse ‐ as defined by each of the studies</p> </section> <section id="CD009005-sec-0056"> <p><b>2. Leaving the study early</b></p> </section> <section id="CD009005-sec-0057"> <p><b>3. Service utilisation</b></p> <p>3.1 Hospital admission<br/> 3.2 Change in hospital status </p> </section> <section id="CD009005-sec-0058"> <p><b>4. Adverse events: clinically important ‐ as defined by individual studies*</b></p> </section> <section id="CD009005-sec-0059"> <p><b>5. Quality of life: clinically important response ‐ as defined by individual studies*</b></p> </section> </section> </section> </section> </section> <section id="CD009005-sec-0060"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009005-sec-0061"> <h4 class="title">Electronic searches</h4> <section id="CD009005-sec-0062"> <h5 class="title">Cochrane Schizophrenia Group’s Trials Register</h5> <p>The Information Specialist searched the Cochrane Schizophrenia Group’s Study‐Based Register of Trials (June 2010, August 2012 and 25 January, 2016) using the following search strategy, which has been developed based on literature review and consulting with the authors of the review: </p> <p>(((antipsychot* or neuroleptic* or drug*) and combin*) or *add‐on* or *addition*or *supplement*or *supplementation*or *cotreatment*or *co‐treatment*or *adjunctive* or *concurrent* or *concomitant* or *simultaneous* or *parallel* or *polypharmacy) in title, abstract or index terms of REFERENCE or (*polytherapy* or *augmentation* or *parallel* or *combined*) in interventions of STUDY </p> <p>In such a study‐based register, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>The Cochrane Schizophrenia Group’s Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD009005-sec-0063"> <h4 class="title">Searching other resources</h4> <section id="CD009005-sec-0064"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD009005-sec-0065"> <h5 class="title">2. Personal contact</h5> <p>Where necessary, we contacted the first author of each included study for information regarding unpublished trials. We noted the outcome of this contact in the <a href="./references#CD009005-sec-0263" title="">Characteristics of included studies</a>, <a href="./references#CD009005-sec-0265" title="">Characteristics of studies awaiting classification</a> tables. </p> </section> </section> </section> <section id="CD009005-sec-0066"> <h3 class="title" id="CD009005-sec-0066">Data collection and analysis</h3> <p>The text below describes data collection and analysis for the 2016 search; the previous data collection and analysis can be seen in <a href="./appendices#CD009005-sec-0232">Appendix 2</a>. </p> <section id="CD009005-sec-0067"> <h4 class="title">Selection of studies</h4> <p>Two review authors JO and SC inspected all abstracts of studies identified as above and identified potentially relevant reports. YH screened the Chinese language studies, and one study in Korean language was inspected by HH. We resolved disagreements by discussion, or where there was still doubt, we acquired the full‐text article for further inspection. We acquired the full‐text articles of relevant reports/abstracts meeting initial criteria for reassessment and carefully inspected for a final decision on inclusion (see <a href="#CD009005-sec-0037">Criteria for considering studies for this review</a>). JO and SC were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked author LC for help, and where it was impossible to decide or if adequate information was not available to make a decision, we added these studies to those awaiting assessment and contacted the authors of the papers for clarification. </p> </section> <section id="CD009005-sec-0068"> <h4 class="title">Data extraction and management</h4> <section id="CD009005-sec-0069"> <h5 class="title">1. Extraction</h5> <p>Review authors JO and SC independently extracted data from all included studies and YH extracted data for Chinese studies. In addition, to ensure reliability, LC extracted data from a random sample of these studies, comprising 10% of the total. Again, we discussed any disagreement and documented decisions. With any remaining problems, LC helped clarify issues and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi‐centre, where possible, we extracted data relevant to each component centre separately. </p> </section> <section id="CD009005-sec-0070"> <h5 class="title">2. Management</h5> <section id="CD009005-sec-0071"> <h6 class="title">2.1 Forms</h6> <p>We adapted the 'Data collection form for intervention reviews' provided by Cochrane to collect data. </p> </section> <section id="CD009005-sec-0072"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> <br/> a) the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD009005-bbs2-0179" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument has not been written or modified by one of the trialists for that particular trial.<br/> <br/> Ideally, the measuring instrument should either be: i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, therefore we noted in Description of studies if this was the case or not. </p> </section> <section id="CD009005-sec-0073"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We did not combined endpoint data and change data, we decided to present the data in the analysis separately (see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). </p> </section> <section id="CD009005-sec-0074"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant data before inclusion. </p> <p>Please note, we entered data from studies of at least 200 participants in the analysis irrespective of the following rules, because skewed data pose less of a problem in large studies. We also entered all relevant change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. </p> <p>For endpoint data:</p> <p>(a) when a scale started from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than 1, it strongly suggests a skew and we excluded these data. If this ratio was higher than one but below 2, there is suggestion of skew. We entered these data and tested whether their inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2 we included these data, because skew is less likely (<a href="./references#CD009005-bbs2-0132" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD009005-bbs2-0166" title="HigginsJPT , GreenS , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>(b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<a href="./references#CD009005-bbs2-0170" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>)) which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and 'S min' is the minimum score. </p> </section> <section id="CD009005-sec-0075"> <h6 class="title">2.5 Common measure</h6> <p>Where relevant, to facilitate comparison between trials, we converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD009005-sec-0076"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we converted continuous outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD009005-bbs2-0186" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:790‐812. ">Overall 1962</a>), or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD009005-bbs2-0170" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this can be considered as a clinically significant response (<a href="./references#CD009005-bbs2-0175" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005</a>; <a href="./references#CD009005-bbs2-0176" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD009005-sec-0077"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for treatment with antipsychotic combinations. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved'), we presented data where the left of the line indicates an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD009005-sec-0078"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors, JO and SC independently assessed the risk of bias of each trial published in English and YH assessed trials published in Chinese by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD009005-bbs2-0167" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, we made the final rating by consensus, with the involvement of LC. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non‐concurrence occurred, we reported this. </p> <p>We noted the level of risk of bias in the text of the review and in <a href="#CD009005-fig-0001">Figure 1</a>, <a href="#CD009005-fig-0002">Figure 2</a> and <a href="./full#CD009005-tbl-0001">summary of findings Table for the main comparison</a>. </p> <div class="figure" id="CD009005-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009005-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009005-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009005-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD009005-sec-0079"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009005-sec-0080"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD009005-bbs2-0141" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD009005-bbs2-0146" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). </p> </section> <section id="CD009005-sec-0081"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated the effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD009005-sec-0082"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009005-sec-0083"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD009005-bbs2-0149" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD009005-bbs2-0140" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD009005-bbs2-0161" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>Where clustering was not accounted for in primary studies, we presented such data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD009005-bbs2-0161" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (Bm) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD009005-bbs2-0150" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC is not reported it will be assumed to be 0.1 (<a href="./references#CD009005-bbs2-0195" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD009005-sec-0084"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD009005-bbs2-0152" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data from the first phase of cross‐over studies. </p> </section> <section id="CD009005-sec-0085"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added and combined within the two‐by‐two table. If data were continuous, we combined data following the formula in section 7.7.3.8  (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD009005-bbs2-0166" title="HigginsJPT , GreenS , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>)<i>.</i> We did not use data where the additional treatment arms were not relevant. </p> </section> </section> <section id="CD009005-sec-0086"> <h4 class="title">Dealing with missing data</h4> <section id="CD009005-sec-0087"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD009005-bbs2-0199" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table by down‐rating quality. We also downgraded quality within the 'Summary of findings' table should loss be 25% to 50% in total. </p> </section> <section id="CD009005-sec-0088"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). We assumed all those leaving the study early to have the same rates of negative outcome as those who completed ‐except for the outcomes of death and adverse effects‐ for these outcomes we used the rate of those who stayed in the study (in that particular arm of the trial) for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change by comparing data only from people who completed the study to that point to the ITT analysis using the above assumptions. </p> </section> <section id="CD009005-sec-0089"> <h5 class="title">3. Continuous</h5> <section id="CD009005-sec-0090"> <h6 class="title">3.1 Attrition</h6> <p>We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported. </p> </section> <section id="CD009005-sec-0091"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either P value or T value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009005-bbs2-0147" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). When only the SE is reported, SDs) are calculated by the formula SD = SE * square root (N). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009005-bbs2-0147" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method, which is based on the SDs of the other included studies (<a href="./references#CD009005-bbs2-0155" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD009005-sec-0092"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD009005-bbs2-0174" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on the statistical approach used. However, we preferred to use the more sophisticated approaches. (e.g. MMRM or multiple‐imputation) and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item "incomplete outcome data" of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD009005-sec-0093"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD009005-sec-0094"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise and discussed in the text if they arose. </p> </section> <section id="CD009005-sec-0095"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise and discussed in the text if they arose. </p> </section> <section id="CD009005-sec-0096"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD009005-sec-0097"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD009005-sec-0098"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD009005-bbs2-0165" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I² depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi²  test, or a confidence interval for I²). An I² estimate greater than or equal to around 50% accompanied by a statistically significant Chi² statistic, can be interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD009005-bbs2-0147" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (<a href="#CD009005-sec-0101">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD009005-sec-0099"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD009005-bbs2-0151" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009005-bbs2-0193" title="SterneJAC , EggerM , MoherD , editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Sterne 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there are 10 or fewer studies, or where all studies were of similar sizes. In future versions of this review, if funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> <section id="CD009005-sec-0100"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose random‐effects model for all analyses. </p> </section> <section id="CD009005-sec-0101"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD009005-sec-0102"> <h5 class="title">1. Subgroup analyses</h5> <p>We presented data in the analyses grouped by the type of antipsychotic used: trials with clozapine in both the monotherapy and combination arm, trials with other atypical drugs in both the monotherapy and combination arms, trials with typical antipsychotic drugs in both arms, or any antipsychotics in both groups, in order to facilitate subgroup analyses (see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). </p> <section id="CD009005-sec-0103"> <h6 class="title">1.1 Primary outcomes</h6> <p>In addition, we also undertook subgroup analyses comparing the results for the following:</p> <p> <ol id="CD009005-list-0003"> <li> <p>enrolment of acutely exacerbated or chronically ill patients;</p> </li> <li> <p>treatment duration &lt;12 weeks vs ≥12 weeks;</p> </li> <li> <p>clozapine vs non‐clozapine combinations; and</p> </li> <li> <p>drug added to clozapine treatment.</p> </li> </ol> </p> </section> </section> <section id="CD009005-sec-0104"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high first, we investigated whether data were entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, we would not pool such data but discuss issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>We performed a meta‐regression for the primary outcome 'No clinically important response' (Please see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply discussed these. We did not undertake sensitivity analyses relating to these. </p> </section> </section> <section id="CD009005-sec-0105"> <h4 class="title">Sensitivity analysis</h4> <section id="CD009005-sec-0106"> <h5 class="title">1. Implication of randomisation</h5> <p>If trials were described in some way as to imply randomisation, we undertook a sensitivity analyses for the primary outcomes. We included these studies in the analyses and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we used relevant data from these studies. </p> </section> <section id="CD009005-sec-0107"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD009005-sec-0086">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported and discussed these results, but continued to employ our assumption. </p> <p>Where assumptions had to be made regarding missing SDs data (see <a href="#CD009005-sec-0086">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. We undertook a sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results, but continued to employ our assumption. </p> </section> <section id="CD009005-sec-0108"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis </p> </section> <section id="CD009005-sec-0109"> <h5 class="title">4. Imputed values</h5> <p>We undertook a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICCs in calculating the design effect in cluster‐randomised trials. </p> <p>If we found substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately </p> </section> <section id="CD009005-sec-0110"> <h5 class="title">5. Fixed and random effects</h5> <p>We synthesised data using a random‐effects model, however, we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether this altered the significance of the results </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009005-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009005-sec-0111"></div> <section id="CD009005-sec-0112"> <h3 class="title">Description of studies</h3> <p>Please also see <a href="./references#CD009005-sec-0263" title="">Characteristics of included studies</a>, <a href="./references#CD009005-sec-0264" title="">Characteristics of excluded studies</a>, <a href="./references#CD009005-sec-0265" title="">Characteristics of studies awaiting classification</a>, and <a href="./references#CD009005-sec-0266" title="">Characteristics of ongoing studies</a>. To try and aid clarity, we have named the studies in an unusual manner. The study tag starts with the duration category (A = long term (over 26 weeks); B = medium term (13 to 26 weeks) and C = short term (up to 12 weeks); the remainder of the tag is the additional drug in the combination antipsychotic group (chlorpromazine has to be shortened to 'CPZ'). Finally, if two studies had similar names an alphabetical tag ( ‐ b, ‐ c) was added. </p> <section id="CD009005-sec-0113"> <h4 class="title">Results of the search</h4> <p>Searches were originally carried out in 2010 and 2012. We supplemented these with a January 2016 search of the Cochrane Schizophrenia Group’s Register of trials. Another trial (<a href="./references#CD009005-bbs2-0126" title="XuL , Ji JueH , ShiH . A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics origin [阿立呱哩治疗抗精神病药物所致 高催乳素血症对照研究]. Chinese Journal of Behavioral Medical Science2006;15(8):718‐20. ">Xu 2006</a>) was added as it appeared as a reference in one of the included trials (<a href="./references#CD009005-bbs2-0026" title="ChenJX , ZhangRZ , LiW , LiuYH , JiangLY , BianQT , et al. Adjunctive treatment of risperidone‐induced hyperprolactinemia with aripiprazole: a randomized, double‐blind, placebo‐controlled study. Chinese Journal of New Drugs2014; Vol. 23:811‐4. ">C +aripiprazole 2014</a>). We included one trial (<a href="./references#CD009005-bbs2-0028" title="RaghuthamanG , VenkateswaranR , KrishnadasR . Adjunctive aripiprazole in risperidone‐induced hyperprolactinaemia: double‐blind, randomised, placebo‐controlled trial. British Journal of Psychiatry Open2015;1(2):172‐7. [DOI: 10.1192/bjpo.bp.115.001248] ">C +aripiprazole 2015b</a>) that was found by methods not described in the protocol (please see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). From these searches 62 trials met the inclusion criteria. Sixty‐two trials were excluded. There are three trials awaiting assessment (<a href="./references#CD009005-sec-0265" title="">Characteristics of studies awaiting classification</a>) and there are three ongoing studies (<a href="#CD009005-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD009005-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Naming of the subgroups: The studies were arranged into four subgroups according to the type of antipsychotics used in both arms: clozapine, atypical antipsychotics other than clozapine, typical antipsychotics and any antipsychotics. Naming of the studies: The study tag starts with the duration category (A = long term (over 26 weeks); B = medium term (13 to 26 weeks) and C = short term (up to 12 weeks); the remainder of the tag is the additional drug in the combination antipsychotic group." data-id="CD009005-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Naming of the subgroups: The studies were arranged into four subgroups according to the type of antipsychotics used in both arms: clozapine, atypical antipsychotics other than clozapine, typical antipsychotics and any antipsychotics. Naming of the studies: The study tag starts with the duration category (A = long term (over 26 weeks); B = medium term (13 to 26 weeks) and C = short term (up to 12 weeks); the remainder of the tag is the additional drug in the combination antipsychotic group. </p> </div> </div> </div> </section> <section id="CD009005-sec-0114"> <h4 class="title">Included studies</h4> <p>The current review includes 94 reports describing 62 trials (4833 participants); 41 studies were two‐arm trials comparing an antipsychotic monotherapy with a combination therapy; 12 trials were three‐arm studies comparing two monotherapies with the combination therapy; four were three‐arm trials comparing one monotherapy with two combinations, and three studies were four‐arm trials comparing two monotherapies with two combinations. <a href="./references#CD009005-bbs2-0027" title="ChenJX , SuYA , BianQT , WeiLH , ZhangRZ , LiuYH , et al. Adjunctive aripiprazole in the treatment of risperidone‐induced hyperprolactinemia: a randomized, double‐blind, placebo‐controlled, dose‐response study. Psychoneuroendocrinology2015;58:130‐40. [DOI: 10.1016/j.psyneuen.2015.04.011] ">C +aripiprazole 2015</a> was a four‐arm trial comparing one combination therapy at three different doses against monotherapy, and, finally, <a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a> was an eight‐arm trial comparing two monotherapies at two different doses with one combination therapy at four different doses. </p> <section id="CD009005-sec-0115"> <h5 class="title">1. Study duration                              </h5> <p>Forty‐seven of the included studies were short term in duration (less than 12 weeks, C). Eight were of medium term (13 to 26 weeks, B) and seven were long term (over 26 weeks, A). </p> </section> <section id="CD009005-sec-0116"> <h5 class="title">2. Design</h5> <p>Most of the included studies presented a parallel longitudinal design. However <a href="./references#CD009005-bbs2-0005" title="BarrettWW , EllsworthRB , ClarkLD , EnnissJ . Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients. Diseases of the Nervous System1957; Vol. 18, issue 6:209‐15. [0012‐3714: (Print); Barrett 1957] ">A +reserpine 1957</a> and <a href="./references#CD009005-bbs2-0042" title="Repo‐TiihonenE , HallikainenT , KivistoP , TiihonenJ . Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co‐treatment. Mental Illness2012; Vol. 4:1‐4. [DOI: 10.4081/mi.2012.e1] ">C +olanzapine 2012b</a>, were cross‐over trials and we only used data from the first phase of these trials until the point of the first cross‐over. Nine were multi‐centre trials; <a href="./references#CD009005-bbs2-0009" title="FleischhackerWW , HeikkinenME , OlieJP , LandsbergW , DewaeleP , McQuadeRD , et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine:a randomized, double‐blind, placebo‐controlled trial. International Journal of Neuropsychopharmacology2010;13(8):1115‐25. [DOI: 10.1017/S1461145710000490] FleischhackerWW , HeikkinenME , OliéJP , LandsbergW , DewaeleP , McQuadeR , et al. Weight change on aripiprazole‐clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16‐week double‐blind study. European Psychiatry2008;23(Suppl 2):114‐5. [DOI: 10.1016/j.eurpsy.2008.01.784; 0924‐9338] KrielW . A multicenter, comparative, randomized, double‐blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. www.sanctr.gov.za/SAClinicalTrials/tabid/169/Default.aspx (first received 15 November 2006). MillarH , FelterC , LandsbergW . The effects of aripiprazole in combination with clozapine: patient functioning results from a double‐blind, 16‐week study in patients with schizophrenia (CN138‐170). Journal of Psychopharmacology2008;22(5):A17. [MEDLINE: Millar 2008 a] ">B +aripiprazole 2008</a> had centres across Europe and in South Africa, <a href="./references#CD009005-bbs2-0052" title="GersonSL . Clozapine alone versus clozapine and risperidone for refractory schizophrenia. New England Journal of Medicine2006;354(17):1846‐8. [1533‐4406: (Electronic); MEDLINE: Honer 2006] GrassG , HellmichM , LewekeFM . Clozapine alone versus clozapine and risperidone for refractory schizophrenia. New England Journal of Medicine2006;354(17):1846‐8. [1533‐4406: (Electronic); MEDLINE: Honer 2006 b2] HonerW . A randomized controlled trial of antipsychotic polypharmacy: clozapine plus risperidone. European Neuropsychopharmacology2007;17(Suppl 4):S200. [DOI: 10.1016/S0924‐977X(07)70237‐7; MEDLINE: Honer 2006 b6] HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00272584?term=NCT00272584&amp;rank=1 (first received 3 January 2006). [MEDLINE: Honer 2006 a] HonerWG , ThorntonAE , ChenEY , ChanRC , WongJO , BergmannA , et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine2006;354(5):472‐82. [1533‐4406: (Electronic); DOI: 10.1056/NEJMoa053222; MEDLINE: Honer 2006] MeltzerHY , Anil YagciogluAE , AkdedeBB . Clozapine alone versus clozapine and risperidone for refractory schizophrenia. New England Journal of Medicine2006;354(17):1846‐8. [1533‐4406: (Electronic); MEDLINE: Honer 2006 b3] ProcyshynRM , WasanKM , ThorntonAE , BarrAM , ChenEY , Pomarol‐ClotetE , et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long‐term clozapine treatment. Journal of Psychiatry Neuroscience2007;32(5):331‐8. [1180‐4882: (Print); MEDLINE: Procyshyn 2007] ">C +risperidone 2006</a> centres in Canada, Germany, China and the UK, and the other seven within their respective countries include (<a href="./references#CD009005-bbs2-0001" title="EssockSM , SchoolerNR , StroupTS , McEvoyJP , RojasI , JacksonC , et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry2011;168(7):702‐8. [DOI: 10.1176/appi.ajp.2011.10060908] ">A +any antipsychotic 2011</a>: USA; <a href="./references#CD009005-bbs2-0012" title="KaneJM , CorrellCU , GoffDC , KirkpatrickB , MarderSR , Vester‐BloklandE , et al. A multicenter, randomized, double‐blind, placebo‐controlled, 16‐week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry2009;70(10):1348‐57. [1555‐2101: (Electronic); DOI: 10.4088/JCP.09m05154yel; Kane 2009] NCT00325689 . A multicenter, randomized, double‐blind, placebo‐controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder.. www.clinicaltrials.gov/ct2/show/NCT00325689?term=NCT00325689&amp;rank=1 (first received May 11 2006). [MEDLINE: Bristol‐Myers 2006] ">B +quet/risp 2009</a>: USA; <a href="./references#CD009005-bbs2-0043" title="YagiG . A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation1976; Vol. 3:351‐403. [MEDLINE: Yagi 1976] ">C +perphenazine 1976</a>: Japan; <a href="./references#CD009005-bbs2-0025" title="LeeBJ , LeeSJ , KimMK , LeeJG , ParkSW , KimGM , et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clinical Psychopharmacology and Neuroscience2013; Vol. 11, issue 2:60‐6. [DOI: 10.9758/cpn.2013.11.2.60] ">C +aripiprazole 2013b</a>: Korea; <a href="./references#CD009005-bbs2-0003" title="ConstantineRJ , AndelR , McPhersonM , TandonR . The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Schizophrenia Research2015;166(1‐3):194‐200. [DOI: 10.1016/j.schres.2015.05.038] ">A +any antipsychotic 2015</a>: USA; <a href="./references#CD009005-bbs2-0045" title="Gunduz‐BruceH . Efficacy of pimozide augmentation for clozapine partial response. www.clinicaltrials.gov/ct2/show/NCT00374244?term=Efficacy+of+pimozide+augmentation+for+clozapine+partial+response&amp;rank=1 (first received 7 September 2006). [MEDLINE: Gunduz‐Bruce 2006] Gunduz‐BruceH . Pimozide for Schizophrenia. Stanley Foundation Research Programs2009. [MEDLINE: Gunduz‐Bruce 2006] Gunduz‐BruceH , OliverS , GueorguievaR , Forselius‐BielenK , D'SouzaDC , ZimoloZ , et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research2013;143(2):344‐7. [DOI: 10.1016/j.schres.2012.11.008] ">C +pimozide 2013</a>: USA; <a href="./references#CD009005-bbs2-0040" title="HattaK , OtachiT , FujitaK , MorikawaF , ItoS , TomiyamaH , et al. Antipsychotic switching versus augmentation among early non‐responders to risperidone or olanzapine in acute‐phase schizophrenia. Schizophrenia Research2014;158(1‐3):213‐22. [DOI: 10.1016/j.schres.2014.07.015] ">C +olan/risp 2014</a>; Japan). </p> </section> <section id="CD009005-sec-0117"> <h5 class="title">3. Participants</h5> <p>A total of 4833 participants are included (average ˜78 people per study). <a href="./references#CD009005-bbs2-0037" title="MossahebN , SacherJ , WieseggerG , KleinN , SpindeleggerC , AsenbaumS , et al. Haloperidol in combination with clozapine in treatment‐refractory patients with schizophrenia. European Neuropsychopharmacology2006;16(suppl 4):416. [DOI: 10.1016/S0924‐977X(06)70524‐7] ">C +haloperidol 2006</a> and <a href="./references#CD009005-bbs2-0002" title="Fricchione PariseV , BallettaG , AddeoL , MannaG . Effectiveness of antipsychotic polypharmacy or monotherapy: real‐world study outcomes. European Neuropsychopharmacology2012;22(Suppl 2):323. [DOI: 10.1016/S0924‐977X(12)70495‐9] ">A +any antipsychotic 2012</a> did not report the country of origin. See also <a href="./appendices#CD009005-sec-0241">Appendix 3</a>. </p> <p>All studies included people with schizophrenia, schizophreniform psychoses, delusional disorder and schizoaffective psychoses. Several means of diagnoses were used. See <a href="./appendices#CD009005-sec-0242">Appendix 4</a>. </p> <p>Most studies included people that had chronic schizophrenia and/or had experienced treatment failure while taking monotherapy antipsychotics. The average age was about 36 years old. </p> </section> <section id="CD009005-sec-0118"> <h5 class="title">4. Settings</h5> <p>Thirty studies included inpatients, 16 studies included outpatients and seven studies both inpatients and outpatients. Two studies (<a href="./references#CD009005-bbs2-0022" title="WangL , ZhangB , XuL , et al. A clinical study on aripiprazole in the treatment of female hyperprolactinemia by haloperidol. China Journal of Health Psychology2009;17(2):194‐5. ">C +aripiprazole 2009</a>; <a href="./references#CD009005-bbs2-0056" title="SiS , YuanC . A comparative trial of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry1999;12:17‐20. ">C +sulpiride 1999</a>) included participants in a community setting. Seven studies did not report the setting (<a href="./references#CD009005-bbs2-0019" title="ShimJ , ShinJ , KellyDL , JungD , SeoY , ConleyRR . Adjunctive treatment with aripiprazole for haloperidol induced hyperprolactinemia: double blind, placebo controlled study. Schizophrenia Bulletin2007;33:460. [Shim 2006 a] ShimJC , JaeYM , ShinJG , JungDW , SeoYS , LiuKH , et al. Drug interactions between aripiprazole and haloperidol: double blind placebo controlled study. European Neuropsychopharmacology2007;17:S438. [Shim 2007 d] ShimJC , ShinJG , KellyDL , JungDU , SeoYS , LiuKH , et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. American Journal of Psychiatry2007;164(9):1404‐10. [0002‐953X: (Print); DOI: 10.1176/appi.ajp.2007.06071075; Shim 2006 a1] ">C +aripiprazole 2007b</a>, <a href="./references#CD009005-bbs2-0026" title="ChenJX , ZhangRZ , LiW , LiuYH , JiangLY , BianQT , et al. Adjunctive treatment of risperidone‐induced hyperprolactinemia with aripiprazole: a randomized, double‐blind, placebo‐controlled study. Chinese Journal of New Drugs2014; Vol. 23:811‐4. ">C +aripiprazole 2014</a>, <a href="./references#CD009005-bbs2-0037" title="MossahebN , SacherJ , WieseggerG , KleinN , SpindeleggerC , AsenbaumS , et al. Haloperidol in combination with clozapine in treatment‐refractory patients with schizophrenia. European Neuropsychopharmacology2006;16(suppl 4):416. [DOI: 10.1016/S0924‐977X(06)70524‐7] ">C +haloperidol 2006</a>, <a href="./references#CD009005-bbs2-0046" title="JiaZ , ZhangZ , JinS . A controlled trial for comparing clozapine combined with pipothiazine palmitate to clozapine alone in the treatment of negative symptoms in schizophrenic patients. Herald of Medicine2000;19:142‐3. ">C +pipotiazine 2000</a>, <a href="./references#CD009005-bbs2-0054" title="NielsenJ , EmborgC , GydesenS , DybbroJ , AagaardJ , HaderupK , et al. Augmenting clozapine with sertindole: a double‐blind, randomized, placebo‐controlled study. Journal Clincal Psychopharmacology2012;32(2):173‐8. [DOI: 10.1097/JCP.0b013e318248dfb8] NielsenJ , Munk‐JorgensenP . Augmenting clozapine with sertindole ‐ a double blinded randomized placebo study. www.clinicaltrials.gov/ct2/show/NCT00345982?term=NCT00345982&amp;rank=1 (first received 28 June 2006). [Nielsen 2006] NielsenRE , LevanderS , ThodeD , NielsenJ . Effects of sertindole on cognition in clozapine‐treated schizophrenia patients. Acta Psychiatrica Scandinavica2012;126(1):31‐9. [DOI: 10.1111/j.1600‐0447.2012.01840.x] ">C +sertindole 2006</a>, <a href="./references#CD009005-bbs2-0055" title="ShilohR , ZemishlanyZ , AizenbergD , RadwanM , SchwartzB , Dorfman‐EtrogP , et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double‐blind, placebo‐controlled study. British Journal of Psychiatry1997;171:569‐73. [0007‐1250: (Print); Shiloh 1997] ShilohR , ZemishlanyZ , AizenbergD , WeizmanA . Sulpiride adjunction to clozapine in treatment‐resistant schizophrenic patients: a preliminary case series study. European Psychiatry1997;12(3):152‐5. [0924‐9338: (Print); MEDLINE: Shiloh 1997] ">C +sulpiride 1997</a>, and <a href="./references#CD009005-bbs2-0061" title="XuB . Observation on the effect of clozapine and sulpiride on negative symptom schizophrenia patients. China Tropical Medicine2006;6(5):806. ">C +sulpiride 2006</a>). </p> </section> <section id="CD009005-sec-0119"> <h5 class="title">5. Interventions</h5> <p>Full details of the doses used are reported in <a href="./references#CD009005-sec-0263" title="">Characteristics of included studies</a> and <a href="./appendices#CD009005-sec-0243">Appendix 5</a>. We arranged the studies into four subgroups according to the type of antipsychotics used in both the monotherapy and combination group: clozapine, atypical antipsychotics other than clozapine, typical antipsychotics and any antipsychotics. </p> <p>In order to determine if the doses used for the antipsychotics in the monotherapy groups were standard, we compared the dosages used in the clinical trials versus dosages suggested by <a href="./references#CD009005-bbs2-0163" title="HasanA , FalkaiP , WobrockT , LiebermanJ , GlenthojB , GattazWF , et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry2012;13(5):318‐78. [DOI: 10.3109/15622975.2012.696143] ">Hasan 2012</a> and <a href="./references#CD009005-bbs2-0159" title="GardnerDM , MurphyAL , O'DonnellH , CentorrinoF , BaldessariniRJ . International consensus study of antipsychotic dosing. American Journal of Psychiatry2010;167(6):686–93. [DOI: 10.1176/appi.ajp.2009.09060802] ">Gardner 2010</a>. We decided not to appraise the interventions in the combination group since there is no evidence for the optimal regimen. </p> <section id="CD009005-sec-0120"> <h6 class="title">Clozapine in both groups</h6> <p>Thirty‐one studies tested clozapine in both the monotherapy and combination arms of the trial. In 26 of these studies an atypical antipsychotic was added to clozapine in the combination therapy, and in five studies a typical antipsychotic was added to clozapine. </p> <p>Three studies (<a href="./references#CD009005-bbs2-0013" title="RichardsonCM , FeldmanS , KellyDL , BallMP , BoggsDL , WeinerE , et al. Metabolic side effects of combined antipsychotic treatment: results from a double blind trial of adjunctive risperidone in clozapine treated people with treatment‐resistant schizophrenia. Schizophrenia Bulletin2009;35(Suppl 1):38‐9. [MEDLINE: Richardson 2009] WeinerE , ConleyRR , BallMP , FeldmanS , GoldJM , KellyDL , et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology2010;35(11):2274‐83. [DOI: 10.1038/npp.2010.101] ">B +risperidone 2010</a>, <a href="./references#CD009005-bbs2-0042" title="Repo‐TiihonenE , HallikainenT , KivistoP , TiihonenJ . Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co‐treatment. Mental Illness2012; Vol. 4:1‐4. [DOI: 10.4081/mi.2012.e1] ">C +olanzapine 2012b</a> and <a href="./references#CD009005-bbs2-0050" title="AkdedeBB , Anil YagciogluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. [1555‐2101: (Electronic); DOI: 10.4088/JCP.v67n1211; MEDLINE: Anil Yagcioglu 2005] AnilE . Risperidone augmented with clozapine for schizophrenia. Stanley Foundation Research Programs2009. [MEDLINE: Anil Yagcioglu 2005] Anil YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005; Vol. 66, issue 1:63‐72. [0160‐6689: (Print); DOI: 10.4088/JCP.v66n0109; MEDLINE: Anil Yagcioglu 2005] YagciogluAEA , AkdedeBBK , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. 24th Congress of the Collegium Internationale Neuro‐Psychopharmacologicum (CINP); 2004 Jun 20‐24; Paris, France. 2004:63‐72. [MEDLINE: Yagcioglu 2004] ">C +risperidone 2005</a>) and of the 31 clozapine studies did not report the doses used. One study (<a href="./references#CD009005-bbs2-0061" title="XuB . Observation on the effect of clozapine and sulpiride on negative symptom schizophrenia patients. China Tropical Medicine2006;6(5):806. ">C +sulpiride 2006</a>) used below‐standard doses of clozapine in the monotherapy group. In 25 studies, standard doses of clozapine were used. <a href="./references#CD009005-bbs2-0045" title="Gunduz‐BruceH . Efficacy of pimozide augmentation for clozapine partial response. www.clinicaltrials.gov/ct2/show/NCT00374244?term=Efficacy+of+pimozide+augmentation+for+clozapine+partial+response&amp;rank=1 (first received 7 September 2006). [MEDLINE: Gunduz‐Bruce 2006] Gunduz‐BruceH . Pimozide for Schizophrenia. Stanley Foundation Research Programs2009. [MEDLINE: Gunduz‐Bruce 2006] Gunduz‐BruceH , OliverS , GueorguievaR , Forselius‐BielenK , D'SouzaDC , ZimoloZ , et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research2013;143(2):344‐7. [DOI: 10.1016/j.schres.2012.11.008] ">C +pimozide 2013</a> reported blood levels and showed higher blood levels of clozapine in the combination group. All except two studies used only oral antipsychotics; <a href="./references#CD009005-bbs2-0011" title="ZhuH , DengD . A study of clozapine combined with or without pipotiazine palmitate in refractory schizophrenia. Journal of Clinical Psychological Medicine2002;12:15‐7. ">B +pipotiazine 2002</a> and <a href="./references#CD009005-bbs2-0046" title="JiaZ , ZhangZ , JinS . A controlled trial for comparing clozapine combined with pipothiazine palmitate to clozapine alone in the treatment of negative symptoms in schizophrenic patients. Herald of Medicine2000;19:142‐3. ">C +pipotiazine 2000</a> included oral clozapine and pipotiazine administered through muscle injection. </p> </section> <section id="CD009005-sec-0121"> <h6 class="title">Other atypical antipsychotics in both groups</h6> <p>Eighteen studies tested atypical antipsychotics (other than clozapine) in both the monotherapy and combination therapy arms of the trial. In two of these trials, a typical antipsychotic was added to an atypical one in the combination therapy, and in the other 16 studies, the combination therapy consisted of two atypical antipsychotics. One study (<a href="./references#CD009005-bbs2-0032" title="JiangL , LeiJ , PengL , et al. Analysis of efficacy of antipsychotics combined with clozapine orally disintegrating tablets in the treatment of schizophrenia with negative symptoms [氯氮平联合抗精神病药治疗精神分裂症阴性 症状的效果分析]. Journal of Bethune Military Medical College2013;11(4):310‐11. ">C +clozapine 2013</a>) did not report the doses used. The rest of the studies used a standard dose of the antipsychotic in the monotherapy group. All except one study used only oral antipsychotics; <a href="./references#CD009005-bbs2-0036" title="ShaftiSS . Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses2009;3(2):97‐102. [DOI: 10.3371/CSRP.3.2.4] ">C +fluphen dec 2009</a> included oral olanzapine and fluphenazine decanoate administered through muscle injection. </p> </section> <section id="CD009005-sec-0122"> <h6 class="title">Typical antipsychotic in both groups</h6> <p>Nine studies tested typical antipsychotics in both arms. In four of these trials, an atypical antipsychotic was added to the typical antipsychotic in the combination therapy, and in five studies, the combination therapy consisted of two typical antipsychotics. Three studies (<a href="./references#CD009005-bbs2-0019" title="ShimJ , ShinJ , KellyDL , JungD , SeoY , ConleyRR . Adjunctive treatment with aripiprazole for haloperidol induced hyperprolactinemia: double blind, placebo controlled study. Schizophrenia Bulletin2007;33:460. [Shim 2006 a] ShimJC , JaeYM , ShinJG , JungDW , SeoYS , LiuKH , et al. Drug interactions between aripiprazole and haloperidol: double blind placebo controlled study. European Neuropsychopharmacology2007;17:S438. [Shim 2007 d] ShimJC , ShinJG , KellyDL , JungDU , SeoYS , LiuKH , et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. American Journal of Psychiatry2007;164(9):1404‐10. [0002‐953X: (Print); DOI: 10.1176/appi.ajp.2007.06071075; Shim 2006 a1] ">C +aripiprazole 2007b</a>; <a href="./references#CD009005-bbs2-0022" title="WangL , ZhangB , XuL , et al. A clinical study on aripiprazole in the treatment of female hyperprolactinemia by haloperidol. China Journal of Health Psychology2009;17(2):194‐5. ">C +aripiprazole 2009</a>; <a href="./references#CD009005-bbs2-0039" title="HigashimaM , TakedaT , NagasawaT , HiraoN , OkaT , NakamuraM , et al. Combined therapy with low‐potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. European Psychiatry2004;19(6):380‐1. [0924‐9338: (Print); DOI: 10.1016/j.eurpsy.2004.07.001; Higashima 2004] ">C +levomepromazine 2004</a>) did not report the doses used. Regarding the monotherapy group, three studies used standard doses, two studies (<a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a>; <a href="./references#CD009005-bbs2-0043" title="YagiG . A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation1976; Vol. 3:351‐403. [MEDLINE: Yagi 1976] ">C +perphenazine 1976</a>) used below‐standard doses, and one study (<a href="./references#CD009005-bbs2-0033" title="ChienCP , ColeJO . Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. American Journal of Psychiatry1973;130(1):13‐8. [0002‐953X: (Print); DOI: 10.1176/ajp.130.1.13; MEDLINE: Chien 1973] ">C +CPZ 1973</a>) used above‐standard doses. All except one study used only oral antipsychotics; <a href="./references#CD009005-bbs2-0033" title="ChienCP , ColeJO . Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. American Journal of Psychiatry1973;130(1):13‐8. [0002‐953X: (Print); DOI: 10.1176/ajp.130.1.13; MEDLINE: Chien 1973] ">C +CPZ 1973</a> included oral chlorpromazine and fluphenazine decanoate administered through muscle injection. </p> </section> <section id="CD009005-sec-0123"> <h6 class="title">Any antipsychotic in both groups</h6> <p>Four trials are included in this subgroup. All except one study included participants already on any combination of antipsychotics who were randomised to monotherapy by discontinuation of one of their current antipsychotics and therefore included any combination of two antipsychotics in the combination arm and any one antipsychotic in the monotherapy arm. Doses were reported as haloperidol, chlorpromazine or olanzapine equivalent. Two trials used standard doses, one study (<a href="./references#CD009005-bbs2-0003" title="ConstantineRJ , AndelR , McPhersonM , TandonR . The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Schizophrenia Research2015;166(1‐3):194‐200. [DOI: 10.1016/j.schres.2015.05.038] ">A +any antipsychotic 2015</a>), used above‐standard doses in both groups. <a href="./references#CD009005-bbs2-0002" title="Fricchione PariseV , BallettaG , AddeoL , MannaG . Effectiveness of antipsychotic polypharmacy or monotherapy: real‐world study outcomes. European Neuropsychopharmacology2012;22(Suppl 2):323. [DOI: 10.1016/S0924‐977X(12)70495‐9] ">A +any antipsychotic 2012</a> included participants treated with monotherapy who were randomised to switch to combination therapy by adding another antipsychotic or to continue receiving monotherapy. The medication to be added was decided by the prescriber and the patient; no doses were reported for this study. </p> </section> </section> <section id="CD009005-sec-0124"> <h5 class="title">6. Outcomes</h5> <p>The included studies provided data for the following outcomes: leaving the study early, clinical improvement, relapse, adverse events (serious or requiring discontinuation, death, movement disorders, prolactin level and weight gain), and used various scales to assess treatment effects in global state, mental state general and specific symptoms, movement disorders and quality of life. </p> <section id="CD009005-sec-0125"> <h6 class="title">6.1 Outcome scales</h6> <p>Only details of scales that provided usable data are shown below. Fifteen different instruments were used to collect scale data. Overall, scale data were poorly presented. </p> <section id="CD009005-sec-0126"> <p><b>Global state</b></p> <p>i. Clinical Global Impression Scale ‐ CGI Scale (<a href="./references#CD009005-bbs2-0162" title="GuyU . Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven‐point scoring system is usually used with low scores showing decreased severity and/or overall improvement. CGI‐Severity (CGI‐S) is one component of the CGI, which rates illness severity and CGI‐Improvement (CGI‐I) rates improvement. High scores indicate a worse outcome. </p> <p>ii. Global Assessment Scale of Functioning Scale (GAF) (<a href="./references#CD009005-bbs2-0135" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Publishing Inc., 2000. ">APA 2000</a>).<br/> This is a modified version of the Global Assessment Scale (GAS) (<a href="./references#CD009005-bbs2-0153" title="EndicottJ , SpitzerRL , FleissJL , CohenJ . The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry1976;33(6):766‐71. ">Endicott 1976</a>), an observer‐rated scale for evaluating the overall functioning of a patient during a specified time period on a continuum from psychological or psychiatric sickness to health. Score ranges from zero to 100, where a higher score indicates a better outcome. </p> </section> <section id="CD009005-sec-0127"> <p><b>Mental state</b></p> <p>i. Positive and Negative Syndrome Scale ‐ PANSS (<a href="./references#CD009005-bbs2-0171" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. ">Kay 1987</a>)<br/> This schizophrenia scale has 30 items, each of which can be defined on a seven‐point scoring system varying from one ‐ absent to seven ‐ extreme. This scale can be divided into three sub‐scales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P), and negative symptoms (PANSS‐N). A low score indicates lesser severity.<br/> <br/> ii. Brief Psychiatric Rating Scale ‐ BPRS (<a href="./references#CD009005-bbs2-0186" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:790‐812. ">Overall 1962</a>)<br/> This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a seven‐point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 126, with high scores indicating more severe symptoms. </p> <p>iii. Scale for the Assessment of Positive Symptoms ‐ SAPS (<a href="./references#CD009005-bbs2-0134" title="AndreasenNC . The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: University of Iowa, 1984. ">Andreasen 1984</a>)<br/> This six‐point scale gives a global rating of positive symptoms such as delusions, hallucinations and disordered thinking. Higher scores indicate more symptoms.<br/> <br/> iv.Scale for the Assessment of Negative Symptoms ‐ SANS (<a href="./references#CD009005-bbs2-0133" title="AndreasenNC . The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa, 1983. ">Andreasen 1983</a>)<br/> This scale allows a global rating of the following negative symptoms: alogia (impoverished thinking), affective blunting, avolition‐apathy, anhedonia‐asociality, and attention impairment. Assessments are made on a six‐point scale from zero (not at all) to five (severe). Higher scores indicate more symptoms. </p> </section> <section id="CD009005-sec-0128"> <p><b>Movement disorders</b></p> <p>i. Barnes Akathisia Scale ‐ BAS (<a href="./references#CD009005-bbs2-0138" title="BarnesTRE . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>)<br/> A scale consisting of four sub‐scales to assess the severity of akathisia: objective rating (zero to three), subjective awareness of restlessness (zero to three), subjective distress related to restlessness (zero to three), and global clinical assessment of akathisia (zero to five). Higher scores indicate more severe akathisia. </p> <p>ii. Abnormal Involuntary Movement Scale ‐ AIMS (<a href="./references#CD009005-bbs2-0162" title="GuyU . Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> The AIMS is a 12‐item scale consisting of a standardised examination followed by questions rating the orofacial, extremity and trunk movements, as well as three global measurements. Each of these 10 items can be scored from zero (none) to four (severe). Two additional items assess the dental status. The AIMS ranges from zero to 40, with higher scores indicating greater severity. </p> <p>iii. Simpson Agnus Scale ‐ SAS (<a href="./references#CD009005-bbs2-0191" title="SimpsonGM , AngusJWS . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;(Suppl 212):11‐9. ">Simpson 1970</a>)<br/> This scale contains 10 items: gait, arm dropping, shoulder shaking. elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor and salivation. Each item is rated between zero and four. A total score is obtained by adding the items and dividing by 10. Scores of up to 0.3 are considered within the normal range. Higher scores indicate greater severity. </p> <p>iv. Udvalg for Kliniske Undersøgelser Side Effect Rating Scale ‐ UKU (<a href="./references#CD009005-bbs2-0177" title="LingjaerdeO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and across‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatrica Scandinavica1987;334(Suppl.):1‐100. ">Lingjaerde 1987</a>)<br/> A comprehensive, clinician‐rated scale, designed to assess the side effects in patients treated with psychotropic medications. The UKU consists of 48 questions. Zero indicates normal; one indicates mild symptoms; two indicates moderate symptoms; and three indicates severe symptoms. Higher scores indicate greater severity. </p> <p>v. Drug‐Induced Extrapyramidal Symptoms Scale ‐ DIEPSS (<a href="./references#CD009005-bbs2-0172" title="KimJH , JungHD , KangUG , JeongSH , AhnYM , ByunHJ , et al. Metric characteristics of the drug‐induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug‐induced movement disorders. Movement Disorders2002;17:1354‐9. ">Kim 2002</a>)<br/> The DIEPSS developed in Japan consists of four sub‐scales for Parkinsonism (five items), akathisia, dystonia, and dyskinesia in combination with a global evaluation. Each item of assessment is rated on a five‐point scale. The severity of each item is graded from zero (normal) to four (severe), higher scores indicate more severe symptoms.<br/> <br/> vi. Extrapyramidal Symptom Rating Scale ‐ ESRS (<a href="./references#CD009005-bbs2-0144" title="ChouinardG , Ross‐ChouinardA , AnnableL , JonesBD . The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences1980;7:233. ">Chouinard 1980</a>)<br/> The ESRS measures movement disorders and scores range from zero to 246. There are sub‐scales for parkinsonism (zero to 108), dystonia (zero to 96), and dyskinesia (zero to 42). Higher scores indicate more severe symptoms. </p> </section> <section id="CD009005-sec-0129"> <p><b>Quality of life</b></p> <p>i. Quality of Life Scale ‐ QLS (<a href="./references#CD009005-bbs2-0164" title="HeinrichDW , HanlonTE , CarpenterWT . The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin1984;10:388‐98. ">Heinrich 1984</a>)<br/> This six‐point quality of life scale has been designed as an outcome instrument for schizophrenic deficit syndrome as well as to measure impaired functioning in studies of chronic schizophrenia, to assess the deficit syndrome's impact on the patient's life. There are seven severity steps (zero to six, six being adequately functioning and zero being deficient). The time frame is one month. Four item categories have been identified by factor analysis 1) interpersonal relationships (seven items), 2) instrumental role (four items), 3) intrapsychic function (seven items) and 4) commonplace objects and activities. </p> <p>ii. Subjective well‐being under neuroleptic treatment scale ‐ SWN (<a href="./references#CD009005-bbs2-0185" title="NaberD . A self‐rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology1995;10:133‐8. ">Naber 1995</a>)<br/> This 38‐item scale with five factors self‐rating scale measures subjective well‐being on neuroleptics. The 20 positively‐ and 18 negatively‐phrased items are rated on a zero to five scale, from not at all, to very much. The five factors are 1) emotional regulation, 2) self‐control, 3) mental functioning, 4) social integration and 5) physical functioning. Low scores predict non‐compliance or discontinuation of treatment in maintenance periods. </p> <p>iii. Short form‐36 ‐ SF‐36 (<a href="./references#CD009005-bbs2-0197" title="WareJE , SherbourneCD . The MOS 36‐Item short‐form health survey (SF‐36®): I. conceptual framework and item selection. Medical Care1992;30(6):473‐83. ">Ware 1992</a>)<br/> This is a 36‐item scale with two components, one measures the physical component and the other the mental component, the scores range from zero to 100. Each scale is subdivided in four factors. For the physical component: 1) physical functioning, 2) role‐physical, 3) bodily pain, and 4) general health; and for the mental component: 1) vitality, 2) social functioning, 3) role‐emotional, and 4) mental health. Lower scores indicate more disability. </p> </section> </section> </section> </section> <section id="CD009005-sec-0130"> <h4 class="title">Excluded studies</h4> <p>We excluded 62 studies from the review (<a href="./references#CD009005-sec-0264" title="">Characteristics of excluded studies</a>). Three trials (<a href="./references#CD009005-bbs2-0066" title="BarbuiC , AccordiniS , NoseM , StroupS , PurgatoM , GirlandaF , et al. Aripiprazole versus haloperidol in combination with clozapine for treatment‐resistant schizophrenia in routine clinical care a randomized, controlled trial. Journal of Clinical Psychopharmacology2011;31(3):266‐73. [DOI: 10.1097/JCP.0b013e318219cba3.] CiprianiA , AccordiniS , NoseM , PurgatoM , GirlandaF , TansellaM , et al. Aripiprazole versus haloperidol in combination with clozapine for treatment‐resistant schizophrenia: a 12‐month, randomized, naturalistic trial. Journal of Clinical Psychopharmacology2013;33(4):533‐7. [DOI: 10.1097/JCP.0b013e318296884f.] NoseM , AccordiniS , ArtioliP , BaraleF , BarbuiC , BeneduceR , et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment‐resistant schizophrenia. Trials2009;10(31):31. [1745‐6215: (Electronic); MEDLINE: Barbui 2006] ">Barbui 2011</a>, <a href="./references#CD009005-bbs2-0124" title="KuwilskyA , KrummB , EnglischS , DressingH , ZinkM . Long‐term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry2010;43(6):216‐20. ZinkM . Clozapine‐augmentation with ziprasidone or risperidone, a randomized, prospective trial. www.clinicaltrials.gov (first received 15 September 2005). [MEDLINE: Zink 2005_a] ZinkM , KuwilskyA , KrummB , DressingH . Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology2009;23(3):305‐14. [0269‐8811: (Print); MEDLINE: Zinc 2009] ">Zink 2009</a>, <a href="./references#CD009005-bbs2-0081" title="JPRN‐UMIN000017047 . A randomized, open‐label clinical trial on the efficacy of blonanserin and olanzapine in patients with schizophrenia and dopamine supersensitivity psychosis. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN‐UMIN000017047(first received 2015). ">JPRN‐UMIN000017047</a>) compared two combinations of antipsychotics but did not include a monotherapy. <a href="./references#CD009005-bbs2-0117" title="吴士玲 , 张金香 . Clinical study of aripiprazole combined with ziprasidone for schizophrenia [阿立哌唑结合齐拉西酮治疗精神分裂症的临床护理观察]. 全国高血压防治知识推广培训班暨健康血压中国行福建漳州会2015;22(1):145. ">Wu 2015</a> compared two combinations of antipsychotics with the addition of a systematic nursing intervention. Eighteen studies were randomised control trials testing an antipsychotic combination, but the combinations did not include two antipsychotics. Twelve studies were randomised control trials comparing different antipsychotic monotherapies with another intervention. Seven studies were randomised control trials evaluating switching strategies to a different antipsychotic. Four trials (<a href="./references#CD009005-bbs2-0109" title="SukegawaT , ItoT , HasegawaM , MizunoY , InagakiA , SakamotoH , et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics. Tottori Journal of Clinical Research2008;1(1):169‐81. ">Sukegawa 2008</a>, <a href="./references#CD009005-bbs2-0110" title="SukegawaT , InagakiA , YamanouchiY , InadaT , YoshioT , YoshimuraR , et al. Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry2014;14(1):103. [DOI: 10.1186/1471‐244X‐14‐103] ">Sukegawa 2014</a>, <a href="./references#CD009005-bbs2-0120" title="UMIN000004511 . The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively. www.umin.ac.jp/ctr/index.htm (first received 10 November 2010). YamanouchiY , SukegawaT , InagakiA , InadaT , YoshioT , YoshimuraR , et al. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high‐dose method. International Journal of Neuropsychopharmacology2015;18:5. [DOI: http://dx.doi.org/10.1093/ijnp/pyu016] ">Yamanouchi 2015</a> and <a href="./references#CD009005-bbs2-0072" title="DRKS00008018 . Are antipsychotics neurotoxic or neuroprotective? A long‐term comparison of two treatment strategies. drks‐neu.uniklinik‐freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00008018 (first received 24 April 2015). ">DRKS00008018</a>) did not evaluate the combination of antipsychotics. <a href="./references#CD009005-bbs2-0105" title="SemenikhinDG , KuchaevaAV , KarpovAM , MikhailovaEB , Murav'evaAV . Additional possibilities for correction of movement disorders induced by neuroleptics in patients with schizophrenia. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova2013;113(11):78‐80. ">Semenikhin 2013</a>, <a href="./references#CD009005-bbs2-0099" title="NCT01939548 . A 12‐week, randomized, phase 2, double‐blind, parallel‐group study of two dose levels of PF‐02545920 compared to placebo in the adjunctive treatment of outpatients with sub‐optimally controlled symptoms of schizophrenia. clinicaltrials.gov/show/NCT01939548 (first received 9 August 2013). ">NCT01939548</a> and <a href="./references#CD009005-bbs2-0100" title="NCT02477670 . Efficacy, safety, and tolerability of AVP‐786 for the treatment of residual schizophrenia. clinicaltrials.gov/show/NCT02477670 (first received 18 June 2015). ">NCT02477670</a> did not test antipsychotic drugs. <a href="./references#CD009005-bbs2-0091" title="MantovaniC , LabateCM , SponholzAJ , deAzevedo MarquesJM , GuapoV G , deSimone Brito dos SantosME , et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated‐blind trial of four intramuscular interventions. Journal of Clinical Psychopharmacology2013;33:306‐12. ">Mantovani 2013</a> and <a href="./references#CD009005-bbs2-0096" title="MythriSV , TharyanP , SunderS , KattulaD , KirubakaranR , AdamsCE . Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine [A comparative study of the effects of an intramuscular injection of zuclopenthixol acetate versus an intramuscular injection of a combination of haloperidol plus promethazine in people with violence or agitation presenting to a psychiatric hospital as an emergency]. Study Protocol(as supplied 2013). ">Mythri 2013</a> did not evaluate participants with a diagnosis of schizophrenia. Ten studies were not randomised controlled trials. <a href="./references#CD009005-bbs2-0077" title="HendersonDC , FanX , CopelandPM , SharmaB , BorbaCP , BoxillR , et al. Aripiprazole added to overweight and obese olanzapine‐treated schizophrenia patients. Joural of Clinical Psychopharmacology2009;29(2):165‐9. [1533‐712X: (Electronic); DOI: 10.1097/JCP.0b013e31819a8dbe; MEDLINE: Henderson 2009 c] ">Henderson 2009</a> was a crossover trial that did not report the results separately for each phase. <a href="./references#CD009005-bbs2-0079" title="JPRN‐UMIN000011710 . New Chiba Refractory Schizophrenia Treatment (CREST)‐LAI study: Effectiveness of risperidone long‐acting injectable for treatment‐resistant schizophrenia. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN‐UMIN000011710(first received 2013). ">JPRN‐UMIN000011710</a> ended without enrolling any patient. </p> <section id="CD009005-sec-0131"> <h5 class="title">1. Awaiting classification</h5> <p>There are three trials awaiting classification (<a href="./references#CD009005-bbs1-0003" title="">Studies awaiting classification</a>): </p> <p><a href="./references#CD009005-bbs2-0125" title="NCT01450514 . Proof‐of‐concept study of pipamperone 15mg added to stable risperidone or paliperidone treatment in chronic schizophrenic and schizoaffective patients with residual symptoms: a Phase I/IIa, randomized, double‐blind, placebo‐controlled trial of 7 weeks. clinicaltrials.gov/show/NCT01450514 (first received 7 October 2011). ">NCT01450514</a> is a clinical trial, which according to the principal investigator, enrolled patients but was concluded prematurely due to funding problems. We tried to obtain the data from the patients that started the trial, but the sponsor decided to keep the data confidential. </p> <p><a href="./references#CD009005-bbs2-0126" title="XuL , Ji JueH , ShiH . A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics origin [阿立呱哩治疗抗精神病药物所致 高催乳素血症对照研究]. Chinese Journal of Behavioral Medical Science2006;15(8):718‐20. ">Xu 2006</a> is a clinical trial that evaluated the effects of aripiprazole compared with placebo on females with hyperprolactinaemia induced by antipsychotics. The placebo used for this trial was vitamin C (100 mg/day), which might have a significant effect on the symptoms of schizophrenia (<a href="./references#CD009005-bbs2-0178" title="MagalhãesPVS , DeanO , AndreazzaAC , BerkM , KapczinskiF . Antioxidant treatments for schizophrenia. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD008919.pub2] ">Magalhães 2016</a>). </p> <p><a href="./references#CD009005-bbs2-0127" title="HanX , YuanYB , YuX . The Chinese first‐episode schizophrenia trial: Background and study design [中國首發精神分裂症臨床試驗(CNFEST):背景和研究設計]. East Asian Archives of Psychiatry2014;24:169‐73. YuanY , YangF , LuZ , WangCY , DengH , ZhaoJ , et al. Effectiveness of three atypical antipsychotic‐initiated treatments in chinese first‐episode schizophrenia: An open randomized clinical trial. Schizophrenia Research2014;153(Suppl. 1):S218. [DOI: 10.1016/S0920‐9964(14)70628‐0] ">Yuan 2014</a> is a clinical trial with multiple treatment stages. In the third stage, participants were able to receive a combinations of antipsychotics. We tried to obtain data regarding the participants who were enrolled on this stage but no response was received. </p> </section> <section id="CD009005-sec-0132"> <h5 class="title">2. Ongoing studies</h5> <p>There are three ongoing studies (<a href="./references#CD009005-sec-0266" title="">Characteristics of ongoing studies</a>). One tests amisulpiride augmentation in clozapine‐unresponsive schizophrenia (<a href="./references#CD009005-bbs2-0129" title="ISRCTN68824876 . Amisulpiride augmentation in clozapine‐unresponsive schizophrenia. www.controlled‐trials.com/ISRCTN68824876 (first received 2 March 2010). NCT01246232 . Amisulpiride augmentation in clozapine‐unresponsive schizophrenia. clinicaltrials.gov/ct2/show/NCT01246232 (first received 22 November 2010). ">ISRCTN68824876</a>), one olanzapine and amisulpiride (<a href="./references#CD009005-bbs2-0130" title="DRKS00003603 . A randomized double‐blind controlled trial to assess the benefits of olanzapine and amisulpiride combination treatment in acutely ill schizophrenia patients ‐ COMBINE. ichgcp.net/clinical‐trials‐registry/NCT01609153 (first received 1 June 2012). NCT01609153 . A randomized double‐blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients ‐ COMBINE. http://ClinicalTrials.gov/show/NCT01609153 (first received 23 May 2012). Schmidt‐KraepelinC . A RCT to assess the benefits of olanzapine and amisulpride combination treatment (COMBINE): design and methods. European Archives of Psychiatry and Clinical Neuroscience2013;263(Suppl. 1):S15‐6. ">Schmidt‐Kraepelin 2013</a>), and one aripiprazole augmentation for participants with weight problems treated with clozapine (<a href="./references#CD009005-bbs2-0128" title="CTRI‐02‐003397 . Efficacy of Aripiprazole adjunctive treatment on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine. A randomized, double‐blind, placebo‐controlled trial. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5862 (first received 14 February 2013). ">CTRI‐02‐003397</a>). </p> </section> </section> </section> <section id="CD009005-sec-0133"> <h3 class="title">Risk of bias in included studies</h3> <p>We prepared a 'Risk of bias' assessment for each trial. For multi‐centre trials providing data for a single centre, we did not assess the risk of bias for each centre. Our judgments regarding the overall risk of bias in individual studies is illustrated in <a href="#CD009005-fig-0001">Figure 1</a> and <a href="#CD009005-fig-0002">Figure 2</a>. </p> <section id="CD009005-sec-0134"> <h4 class="title">Allocation</h4> <p>Of the 62 trials analysed in this review, 18 reported an adequate generation of allocation sequence. In two studies (<a href="./references#CD009005-bbs2-0014" title="LiuQH , LiXL , ZhangYQ , JinSL , LiZC , WangNS , et al. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chinese Journal of Psychiatry1996;29(2):87‐90. [MEDLINE: Liu 1996] ">B +sulpiride 1996</a>; <a href="./references#CD009005-bbs2-0036" title="ShaftiSS . Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses2009;3(2):97‐102. [DOI: 10.3371/CSRP.3.2.4] ">C +fluphen dec 2009</a>) the risk of bias was high for sequence generation as a quasi‐randomised method was used, and three studies (<a href="./references#CD009005-bbs2-0035" title="ChaC , HuiG , QuingG . Evaluation of therapeutic effect with chlorpromazine and clozapine for treatment of schizophrenia. Xinxiang Med Stud1999;16:311‐6. ">C +CPZ 1999</a>, <a href="./references#CD009005-bbs2-0056" title="SiS , YuanC . A comparative trial of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry1999;12:17‐20. ">C +sulpiride 1999</a>, <a href="./references#CD009005-bbs2-0057" title="XaoH . A double‐blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Mental Health1999;12:250‐1. ">C +sulpiride 1999b</a>) had a high risk of bias as they randomised according to hospital admission order or time.  In all remaining studies, the method of assignment was unclear. Similarly, methods used to conceal allocation had a low risk of bias in 16 trials, high risk of bias in one and unclear in the remainder (please see <a href="#CD009005-sec-0261">Differences between protocol and review</a>). </p> </section> <section id="CD009005-sec-0135"> <h4 class="title">Blinding</h4> <p>In 19 studies, participants, care providers, and outcome assessors were blinded, 12 studies were high risk of bias for blinding as they were either open‐label studies or the participants and personnel were not blinded; the risk of bias was unclear for the remaining 31 trials. </p> </section> <section id="CD009005-sec-0136"> <h4 class="title">Incomplete outcome data</h4> <p>There was a low risk of bias for incomplete data in 33 studies, an unclear risk of bias in nine studies, and a high risk of bias in 20 trials. </p> </section> <section id="CD009005-sec-0137"> <h4 class="title">Selective reporting</h4> <p>Twenty‐three studies were free from selective reporting, 36 studies had a high risk of bias for selective reporting, and three had an unclear risk of bias. </p> </section> <section id="CD009005-sec-0138"> <h4 class="title">Other potential sources of bias</h4> <p>Twenty‐three studies were free from other biases, eight were subject to other biases and in the remaining studies the risk of bias was unclear. </p> </section> </section> <section id="CD009005-sec-0139"> <h3 class="title" id="CD009005-sec-0139">Effects of interventions</h3> <p>See: <a href="./full#CD009005-tbl-0001"><b>Summary of findings for the main comparison</b> Combinations of antipsychotic drugs compared to single antipsychotic drugs for schizophrenia</a> </p> <p>Where data were available, they were arranged into four subgroups according to the type of antipsychotics used in both arms: clozapine, atypical antipsychotics other than clozapine, typical antipsychotics and any antipsychotics. Studies were also named according to the add‐on antipsychotic (see <a href="#CD009005-sec-0112">Description of studies</a>), so it is possible to see in each analysis more information about the combination of antipsychotics used in each study, as well as the length of follow‐up. </p> <p>Where data were missing, such as standard deviations for continuous outcomes, we imputed these data using trials with similar means for that scale. We used the mean difference and reported the data separately for different scales within an outcome (<a href="./appendices#CD009005-sec-0252">Appendix 6</a>). </p> <p>For studies with more than two comparison groups we combined data, i.e. if the study tested different antipsychotics in two monotherapy groups or two combination groups. Where studies had two monotherapy groups, for studies with typical drugs in both groups data from the monotherapy groups were combined; for studies with clozapine in both groups, only data from the clozapine monotherapy group was added to the data analysis. </p> <section id="CD009005-sec-0140"> <h4 class="title">1. COMPARISON 1: ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY</h4> <p>This particular comparison has 63 outcomes.</p> </section> <section id="CD009005-sec-0141"> <h4 class="title">1.1 Clinical response: 1. No clinically important response ‐ not improved</h4> <p>We found twenty‐nine trials (N = 2398), with six weeks to three years follow‐up. We found that the use combination of antipsychotics may reducing the risk of no clinical response (RR 0.73 CI 0.64 to 0.83; <a href="./references#CD009005-fig-0004" title="">Analysis 1.1</a>; <i>very low quality evidence</i>). Results showed an important heterogeneity (I<sup>2</sup> = 54%). When we split the trials by length of follow‐up, the results remain but there is no heterogeneity for the longer‐term trials ‐ the heterogeneity may be due to the short‐term trials. </p> <section id="CD009005-sec-0142"> <h5 class="title">1.1.1 clozapine in both groups</h5> <p>Trials with clozapine (N = 1127); in both groups also favoured the combination therapy (RR 0.66 CI 53 to 0.83), but had high heterogeneity (I² = 64%) and no obviously outlying trials. </p> </section> <section id="CD009005-sec-0143"> <h5 class="title">1.1.2 other atypical in both groups</h5> <p>Seven trials tested atypical in both groups (N = 674). There was not a clear difference between antipsychotic combinations and antipsychotic monotherapy within this subgroup (RR 0.95 CI 0.83 to 1.09). </p> </section> <section id="CD009005-sec-0144"> <h5 class="title">1.1.3 typical drugs in both groups</h5> <p>We found five trials to be relevant to this subgroup, which included a total of 597 participants. For this outcome, we did find evidence that antipsychotic combinations reduced the risk of no response when compared with antipsychotic monotherapy (RR 0.64 CI 0.49 to 0.84). For this subgroup heterogeneity is moderately high (I<sup>2</sup> = 47%) but when the outlying trial <a href="./references#CD009005-bbs2-0043" title="YagiG . A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation1976; Vol. 3:351‐403. [MEDLINE: Yagi 1976] ">C +perphenazine 1976</a> is removed the results show no heterogeneity. </p> </section> </section> <section id="CD009005-sec-0145"> <h4 class="title">1.2 Clinical response: 2. Relapse</h4> <p>Three trials (N = 512), with follow‐up durations of eight weeks, one year and three years, respectively provided data regarding relapse. Results showed high heterogeneity (I² = 81%), when the outlying study (<a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a>) is removed heterogeneity is restored. But as this trial carries more than 10% of the weighting for this outcome, the results were not pooled. <a href="./references#CD009005-bbs2-0006" title="WangCH , QinTF , LinYL , ZhaoXF . A clinical effect and following‐up study about sulpiride and clozapine for 105 cases of the schizophrenia type. Journal of Xinxiang Medical College1994;11(2):148‐51. [MK_007527] ">A +sulpiride 1994</a> and <a href="./references#CD009005-bbs2-0043" title="YagiG . A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation1976; Vol. 3:351‐403. [MEDLINE: Yagi 1976] ">C +perphenazine 1976</a> found no difference between the two interventions. <a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a> found that antipsychotics combinations is more effective for preventing relapse when compared to monotherapy. </p> </section> <section id="CD009005-sec-0146"> <h4 class="title">1.3 Leaving the study early</h4> <p>Forty‐three trials (N = 3137), with six weeks to one year follow‐up found no difference in the number of people leaving the study early (RR 0.90 CI 0.76 to 1.07; <a href="./references#CD009005-fig-0006" title="">Analysis 1.3</a>, <i>low‐quality evidence</i>). Subgroup analysis showed no important difference between groups. </p> </section> <section id="CD009005-sec-0147"> <h4 class="title">1.4 Service utilisation: Hospital admission</h4> <p>Three trials (N = 202), with follow‐up duration of eight, ten weeks and six months, respectively, provided data on hospital admission. Two trials tested clozapine in both groups, and the other tested any antipsychotics in both groups. A combination of antipsychotics was not superior or inferior to antipsychotic monotherapy in preventing hospital admission (RR 0.96 CI 0.36 to 2.55; <a href="./references#CD009005-fig-0007" title="">Analysis 1.4</a>, <i>very low‐quality evidence</i>). None of the subgroups showed different results. </p> </section> <section id="CD009005-sec-0148"> <h4 class="title">1.5 Clinical response: 3. Global state ‐ i. average severity score (CGI‐S scale, high = bad) </h4> <p>For this outcome we found seven relevant studies which provided endpoint data regarding global state on the severity component of the CGI scale, with six weeks to three years follow‐up involving 496 participants. For this outcome, we did not find evidence that antipsychotic combinations was different in its effects compared with antipsychotic monotherapy (MD ‐0.13 CI ‐0.31 to 0.06, <a href="./references#CD009005-fig-0008" title="">Analysis 1.5</a>). This outcome had moderate levels of heterogeneity (I<sup>2</sup> = 44%). None of the subgroups showed different results. </p> </section> <section id="CD009005-sec-0149"> <h4 class="title">1.6 Clinical response: 3. Global state ‐ ii. change in severity score (CGI‐S scale, high = bad) </h4> <p>Three relevant (N = 233) studies involving 233 participants only provided change data regarding this scale. For this outcome, we did not find evidence that antipsychotic combinations was clearly different in its effects compared with antipsychotic monotherapy (MD 0.11 CI ‐0.09 to 0.32; <a href="./references#CD009005-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD009005-sec-0150"> <h4 class="title">1.7 Clinical response: 4. Global state ‐ average improvement score (CGI‐I scale, high = bad) </h4> <p>Four trials, with ten to 16 weeks follow‐up, measured global state on the improvement component of the CGI scale. We found that the combination therapy may improve clinical response when compared to monotherapy (MD ‐0.36 CI ‐0.58 to ‐0.13; <a href="./references#CD009005-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD009005-sec-0151"> <h4 class="title">1.8 Clinical response: 5. Global state ‐ i. average functioning score (GAF scale, high = good) </h4> <p>We identified three studies relevant to this outcome, with 6 to 12 weeks follow‐up, involving 107 participants. For this outcome heterogeneity is high (I<sup>2</sup> = 80%). When <a href="./references#CD009005-bbs2-0050" title="AkdedeBB , Anil YagciogluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. [1555‐2101: (Electronic); DOI: 10.4088/JCP.v67n1211; MEDLINE: Anil Yagcioglu 2005] AnilE . Risperidone augmented with clozapine for schizophrenia. Stanley Foundation Research Programs2009. [MEDLINE: Anil Yagcioglu 2005] Anil YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005; Vol. 66, issue 1:63‐72. [0160‐6689: (Print); DOI: 10.4088/JCP.v66n0109; MEDLINE: Anil Yagcioglu 2005] YagciogluAEA , AkdedeBBK , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. 24th Congress of the Collegium Internationale Neuro‐Psychopharmacologicum (CINP); 2004 Jun 20‐24; Paris, France. 2004:63‐72. [MEDLINE: Yagcioglu 2004] ">C +risperidone 2005</a> is removed, heterogeneity is restored but as this trial carries more than 10% of the weighting for this outcome, the results were not pooled and we only presented the data for the subgroups: </p> <section id="CD009005-sec-0152"> <h5 class="title">1.8.1 Clozapine in both groups</h5> <p>There is a single trial in this subgroup, which included a total of 30 participants. We found evidence that antipsychotics combination is worse than monotherapy for improvement of the global state (MD ‐4.5 CI ‐8.38 to ‐0.62; <a href="./references#CD009005-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD009005-sec-0153"> <h5 class="title">1.8.2 Other atypical drugs in both groups</h5> <p>There are two relevant trials in this subgroup, which included a total of 77 participants. We found evidence that the use antipsychotic combinations when compared to antipsychotic monotherapy improves the global state when assessed with the GAF scale (MD 8.73 CI 1.56 to 15.9; <a href="./references#CD009005-fig-0011" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD009005-sec-0154"> <h4 class="title">1.9 Clinical response: 5. Global state ‐ ii. change in functioning score (GAF scale, high = good) </h4> <p>We found three studies (N = 349) which provided only change data for the GAF scale, we did not find evidence of a clear difference between the two treatments in this comparison (MD 0.27 CI ‐1.42 to 1.97; <a href="./references#CD009005-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD009005-sec-0155"> <h4 class="title">1.10 Mental state: 1. Overall ‐ a.i average total score (PANSS scale, high = bad)</h4> <p>We identified 11 studies relevant to this outcome involving 721 participants. We did not find evidence of a clear difference between the two treatments in this comparison. This outcome had important levels of heterogeneity (I<sup>2</sup> = 58%). When <a href="./references#CD009005-bbs2-0015" title="MuscatelloMR , PandolfoG , MicoU , Lamberti CastronuovoE , AbenavoliE , ScimecaG , et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2014;34(1):129‐33. [DOI: 10.1097/JCP.0000000000000042] ">B +ziprasidone 2014</a> and <a href="./references#CD009005-bbs2-0047" title="NiJ , JangL , HongX . Therapeutic effects of clozapine, risperidone and their combination in the treatment of schizophrenia. Health Psychology2001;3:181‐2. ">C +risperidone 2001</a> are removed, heterogeneity is decreased but as these trials carry more than 10% of the weighting for this outcome, the results were not pooled. </p> </section> <section id="CD009005-sec-0156"> <h4 class="title">1.11 Mental state: 1. Overall ‐ a.ii change in total score (PANSS scale, high = bad)</h4> <p>Eight studies (N = 406) only provided change data for the PANSS scale, we did not find evidence of a clear difference between the two treatments in this comparison (MD ‐1.05 CI ‐3.42 to 1.32; <a href="./references#CD009005-fig-0014" title="">Analysis 1.11</a>). Subgroup analysis showed no difference. </p> </section> <section id="CD009005-sec-0157"> <h4 class="title">1.12 Mental state: 1. Overall ‐ b.i. average total score (BPRS scale, high = bad)</h4> <p>We found 21 trials (N = 1082), with six weeks to six months follow‐up, who reported data for mental state on the BPRS scale, but results showed high heterogeneity (I² = 92%; <a href="./references#CD009005-fig-0015" title="">Analysis 1.12</a>). Removal of the outlying studies <a href="./references#CD009005-bbs2-0057" title="XaoH . A double‐blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Mental Health1999;12:250‐1. ">C +sulpiride 1999b</a> and <a href="./references#CD009005-bbs2-0059" title="ZouG , HuangY , ZouS , YangY . A comparative trial of the beneficial effects of sulpiride combined with clozapine in the treatment of refractory schizophrenia. Journal of Yichun University2003;25:94‐6. ">C +sulpiride 2003</a> reduces heterogeneity for the clozapine subgroup (I² = 47%), but not for the pooled results (I² = 81%). Data were, therefore, not pooled for this outcome. </p> </section> <section id="CD009005-sec-0158"> <h4 class="title">1.13 Mental state: 1. Overall ‐ b.ii change total score (BPRS scale, high = bad)</h4> <p>We identified one study which only provided change data for this outcome involving 100 participants. We did find evidence that antipsychotic combinations improved the overall mental state when evaluated with the BPRS scale (MD ‐2.72 CI ‐5.37 to ‐0.07; <a href="./references#CD009005-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD009005-sec-0159"> <h4 class="title">1.14 Mental state: 2. Specific ‐ a. positive symptoms ‐ no clinical improvement</h4> <p>Two trials, with six and 10 weeks follow‐up, reported binary data for no clinical improvement on positive symptoms, but the results showed high heterogeneity (I² = 80; <a href="./references#CD009005-fig-0017" title="">Analysis 1.14</a>). Data were, therefore, not pooled for this outcome. None of the studies showed a difference between the two groups. </p> </section> <section id="CD009005-sec-0160"> <h4 class="title">1.15 Mental state: 2. Specific ‐ b. positive symptoms ‐ i. average score (PANSS scale, high = bad) </h4> <p>For this outcome we found four relevant studies involving 158 participants. We found evidence that participants assigned to antipsychotics combinations had a poorer response to the positive symptoms than patients assigned to antipsychotics monotherapy (MD 2.02 CI 0.90 to 3.14; <a href="./references#CD009005-fig-0018" title="">Analysis 1.15</a>). The results are due to the trials in the subgroup where clozapine was used in both groups. </p> </section> <section id="CD009005-sec-0161"> <h4 class="title">1.16 Mental state: 2. Specific ‐ b. positive symptoms ‐ ii. change score (PANSS scale, high = bad) </h4> <p>We identified nine studies who reported only change data for the positive symptoms assessed with the PANSS scale. We did not find evidence of a clear difference between antipsychotic combinations and antipsychotic monotherapy (MD 0.01 CI ‐0.45 to 0.47; <a href="./references#CD009005-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD009005-sec-0162"> <h4 class="title">1.17 Mental state: 2. Specific ‐ b. positive symptoms ‐ iii. average score (BPRS scale, high = bad) </h4> <p>We identified three studies, with a follow‐up time between eight and 16 weeks, we did not find evidence of a clear difference between antipsychotic combinations and antipsychotic monotherapy (MD ‐1.02 CI ‐2.42 to 0.38; <a href="./references#CD009005-fig-0020" title="">Analysis 1.17</a>). This outcome had moderate levels of heterogeneity (I<sup>2</sup> = 41%). We did not find a difference in the results between subgroups. </p> </section> <section id="CD009005-sec-0163"> <h4 class="title">1.18 Mental state: 2. Specific ‐ b. positive symptoms ‐ iv. change data (BPRS scale, high = bad) </h4> <p>We identified one study (N = 17) which only reported change data for the positive symptoms when assessed with the BPRS scale. We did not find evidence of a clear difference between antipsychotic combinations and antipsychotic monotherapy (MD ‐0.3 CI ‐1.16 to 0.56; <a href="./references#CD009005-fig-0021" title="">Analysis 1.18</a>) </p> </section> <section id="CD009005-sec-0164"> <h4 class="title">1.19 Mental state: 2. Specific ‐ b. positive symptoms ‐ v. average score (SAPS scale, high = bad) </h4> <p>We identified one study relevant to this outcome involving 28 participants. For this outcome, we did find evidence that antipsychotic combinations is better than monotherapy for the positive symptoms when assessed with the SAPS scale (MD ‐6.76 CI ‐11.91 to ‐1.61, <a href="./references#CD009005-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD009005-sec-0165"> <h4 class="title">1.20 Mental state: 2. Specific ‐ b. positive symptoms ‐ vi. change score (SAPS scale, high = bad) </h4> <p>One study provided only change data for this scale. We found evidence that antipsychotic combinations is better at reducing the positive symptoms when compared to monotherapy (MD ‐5.8 CI ‐11.33 to ‐0.27, <a href="./references#CD009005-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD009005-sec-0166"> <h4 class="title">1.21 Mental state: 3. Specific ‐ a. negative symptoms ‐ no clinical improvement</h4> <p>Three trials, with six to ten weeks follow‐up, reported binary data for no clinical improvement on negative symptoms, but the results showed high heterogeneity (I² = 65; <a href="./references#CD009005-fig-0024" title="">Analysis 1.21</a>). Removal of <a href="./references#CD009005-bbs2-0050" title="AkdedeBB , Anil YagciogluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. [1555‐2101: (Electronic); DOI: 10.4088/JCP.v67n1211; MEDLINE: Anil Yagcioglu 2005] AnilE . Risperidone augmented with clozapine for schizophrenia. Stanley Foundation Research Programs2009. [MEDLINE: Anil Yagcioglu 2005] Anil YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005; Vol. 66, issue 1:63‐72. [0160‐6689: (Print); DOI: 10.4088/JCP.v66n0109; MEDLINE: Anil Yagcioglu 2005] YagciogluAEA , AkdedeBBK , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. 24th Congress of the Collegium Internationale Neuro‐Psychopharmacologicum (CINP); 2004 Jun 20‐24; Paris, France. 2004:63‐72. [MEDLINE: Yagcioglu 2004] ">C +risperidone 2005</a> restores homogeneity and the results become significant (RR 0.80 CI 0.65 to 0.98), but as this trial carries more than 10% of the weighting for this outcome, the results were not pooled. </p> </section> <section id="CD009005-sec-0167"> <h4 class="title">1.22 Mental state: 3. Specific ‐ b. negative symptoms ‐ i. average score (PANSS scale, high = bad) </h4> <p>For this outcome we found five relevant studies involving 194 participants. For this outcome heterogeneity is high (I<sup>2</sup> = 57%). The heterogeneity is due to <a href="./references#CD009005-bbs2-0008" title="HoriH , YoshimuraR , KatsukiA , SugitaAI , AtakeK , NakamuraJ . Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of Psychiatric Research2013;47(12):1843‐8. [DOI: 10.1016/j.jpsychires.2013.08.024] ">B +any antipsychotic 2013</a> which belongs to the subgroup 'Any antipsychotic in both groups', when this trial is removed heterogeneity is resolved. Because this trial carries more than 10% of the weighting for this outcome, the results were only presented in subgroups. </p> <section id="CD009005-sec-0168"> <h5 class="title">1.22.1 clozapine in both groups</h5> <p>We found three trials to be relevant to this subgroup (N = 119). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 0.31 CI ‐1.18 to 1.8; <a href="./references#CD009005-fig-0025" title="">Analysis 1.22</a>). </p> </section> <section id="CD009005-sec-0169"> <h5 class="title">1.22.2 other atypical drugs in both groups</h5> <p>We found one trial to be relevant to this subgroup, with a total of 36 people. For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 1.2 CI ‐1.51 to 3.91; <a href="./references#CD009005-fig-0025" title="">Analysis 1.22</a>). </p> </section> <section id="CD009005-sec-0170"> <h5 class="title">1.22.3 Any antipsychotic in both groups</h5> <p>We found one trial to be relevant to this subgroup, with a total of 39 people. We found evidence that antipsychotics combinations is worse for improving the negative symptoms when compared to antipsychotic monotherapy (MD 3.3 CI 1.6 to 5.0; <a href="./references#CD009005-fig-0025" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD009005-sec-0171"> <h4 class="title">1.23 Mental state: 3. Specific ‐ b. negative symptoms ‐ ii. change score (PANSS scale, high = bad) </h4> <p>We identified nine studies involving 891 participants. The studies only reported change score. We did not find evidence of a clear difference between antipsychotic combinations and antipsychotic monotherapy (MD 0.02 CI ‐0.54 to 0.58, <a href="./references#CD009005-fig-0026" title="">Analysis 1.23</a>). No important difference was found between subgroups. </p> </section> <section id="CD009005-sec-0172"> <h4 class="title">1.24 Mental state: 3. Specific ‐ b. negative symptoms ‐ iii. average score (BPRS scale, high = bad) </h4> <p>We identified two studies relevant to this outcome. We did not pooled the data because heterogeneity was high (I<sup>2</sup> = 56%) and we only present the results by subgroups. </p> <section id="CD009005-sec-0173"> <h5 class="title">1.24.1 clozapine in both groups</h5> <p>There is a single trial in this subgroup, which included a total of 61 participants. There was not a clear difference between antipsychotic combinations and antipsychotic monotherapy within this subgroup (MD ‐4.3 CI ‐12.25 to 3.65; <a href="./references#CD009005-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD009005-sec-0174"> <h5 class="title">1.24.2 other atypical drugs in both groups</h5> <p>There is a single trial in this subgroup, which included a total of 40 participants. We found evidence that antipsychotic combinations is worse at improving the negative symptoms when compared to antipsychotic monotherapy (MD 1.9 CI 0.69 to 3.11; <a href="./references#CD009005-fig-0027" title="">Analysis 1.24</a>) </p> </section> </section> <section id="CD009005-sec-0175"> <h4 class="title">1.25 Mental state: 3. Specific ‐ b. negative symptoms ‐ iv. change score (BPRS scale, high = bad) </h4> <p>For this outcome we found a single trial (N = 12). We did not find evidence of a clear difference between antipsychotic combinations and antipsychotic monotherapy (MD 0.2 CI ‐0.29 to 0.69; <a href="./references#CD009005-fig-0028" title="">Analysis 1.25</a>) </p> </section> <section id="CD009005-sec-0176"> <h4 class="title">1.26 Mental state: 3. Specific ‐ b. negative symptoms ‐ v. average score (SANS scale, high = bad) </h4> <p>Eleven trials, with six to 16 weeks follow‐up, measured negative symptoms on the SANS scale (<a href="./references#CD009005-fig-0029" title="">Analysis 1.26</a>). These results were not pooled in the analysis as they showed high heterogeneity (I² = 96%). Most studies tested clozapine in both groups, but again with high heterogeneity (I² = 93%). Removing the outlying trials <a href="./references#CD009005-bbs2-0051" title="JosiassenRC , JosephA , KohegyiE , StokesS , DadvandM , PaingWW , et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐controlled trial. 9th International Congress on Schizophrenia Research; 2003 Mar 29‐Apr 2; Colorado Springs, CO. 2003:130‐6. [MEDLINE: Josiassen 2003] JosiassenRC , JosephA , KohegyiE , StokesS , DadvandM , PaingWW , et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry2005;162(1):130‐6. [0002‐953X: (Print); DOI: 10.1176/appi.ajp.162.1.130; MEDLINE: Josiassen 2005] ">C +risperidone 2005b</a>, <a href="./references#CD009005-bbs2-0014" title="LiuQH , LiXL , ZhangYQ , JinSL , LiZC , WangNS , et al. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chinese Journal of Psychiatry1996;29(2):87‐90. [MEDLINE: Liu 1996] ">B +sulpiride 1996</a>, <a href="./references#CD009005-bbs2-0057" title="XaoH . A double‐blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Mental Health1999;12:250‐1. ">C +sulpiride 1999b</a> and <a href="./references#CD009005-bbs2-0059" title="ZouG , HuangY , ZouS , YangY . A comparative trial of the beneficial effects of sulpiride combined with clozapine in the treatment of refractory schizophrenia. Journal of Yichun University2003;25:94‐6. ">C +sulpiride 2003</a> does restore heterogeneity for the clozapine subgroup but does not affect the overall results. They account for more than 10% of the weighting and so again, results are not pooled. No important difference was found for other atypical drugs or typical in both groups. </p> </section> <section id="CD009005-sec-0177"> <h4 class="title">1.27 Mental state: 3. Specific ‐ b. negative symptoms ‐ vi. average score (SANS scale, high = bad) </h4> <p>We found one trial who only reported change data for this scale, which included a total of 28 participants. We found evidence that the use of antipsychotic combinations is better at improving the negative symptoms when compared to antipsychotic monotherapy (MD ‐6.80 CI ‐12.65 to ‐0.95; <a href="./references#CD009005-fig-0030" title="">Analysis 1.27</a>). </p> </section> <section id="CD009005-sec-0178"> <h4 class="title">1.28 Mental state: 4. Specific ‐ aggression/agitation ‐ average score (BPRS scale, high = bad) </h4> <p>One trial (N = 12), with a follow‐up duration of eight weeks, only provided data for change in aggression/agitation symptoms when assessed with the BPRS scale. We found evidence in favour of combination therapy in improving aggression/agitation symptoms (MD ‐1.30 CI ‐2.32 to ‐0.28; <a href="./references#CD009005-fig-0031" title="">Analysis 1.28</a>). </p> </section> <section id="CD009005-sec-0179"> <h4 class="title">1.29 Adverse events: 1. General ‐ a. serious event or requiring discontinuation</h4> <p>Thirty trials (N = 2398), with six weeks to eight months follow‐up, did not find an important difference in the number of adverse events that were serious or required discontinuation (RR 1.05 CI 0.65 to 1.69; <a href="./references#CD009005-fig-0032" title="">Analysis 1.29</a>, <i>very low quality of evidence</i>). None of the subgroups of antipsychotics showed a significant difference. </p> </section> <section id="CD009005-sec-0180"> <h4 class="title">1.30 Adverse events: 1. General ‐ b. death (suicide or non‐suicide deaths)</h4> <p>Only four trials reported on deaths, with follow‐up durations of eight to 12 weeks. There was only one death reported in the combination group and no deaths in the monotherapy group <a href="./references#CD009005-fig-0033" title="">Analysis 1.30</a>. </p> </section> <section id="CD009005-sec-0181"> <h4 class="title">1.31 Adverse events: 2. Movement disorders ‐ a. any</h4> <p>Twenty trials, with 30 days to three years follow‐up, provided binary data regarding movement disorders. No difference was found between combination therapy and monotherapy in the number of participants experiencing movement disorders (RR 1.07 CI 0.92 to 1.25; N = 1868; studies = 20; <a href="./references#CD009005-fig-0034" title="">Analysis 1.31</a>), and none of the subgroups of antipsychotics showed a significant difference. </p> <p>Movement disorders were also measured on eight scales (Barnes Akathisia Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), Simpson Angus Scale (SAS), Udvalg for Kliniske Undersøgelser (UKU), Treatment Emergent Symptom Scale (TESS), Extrapyramidal SymptomRating Scale (ESRS) and Drug‐Induced Extrapyramidal Symptoms Scale (DIEPSS). However, much of the data were considerably skewed and are reported in <a href="./appendices#CD009005-sec-0253">Appendix 7</a>. </p> </section> <section id="CD009005-sec-0182"> <h4 class="title">1.32 Adverse events: 2. Movement disorders ‐ b.i. average scores (SAS, high = bad)</h4> <p>Nine trials reported on movement disorders using the SAS, but in six of them, the data were very skewed and not added to the analysis. The pooled data for the three remaining trials showed very high heterogeneity (I² = 99%; <a href="./references#CD009005-fig-0035" title="">Analysis 1.32</a>) and so were not pooled. The heterogeneity might be due to the difference in the properties of the drugs, as <a href="./references#CD009005-bbs2-0036" title="ShaftiSS . Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses2009;3(2):97‐102. [DOI: 10.3371/CSRP.3.2.4] ">C +fluphen dec 2009</a> is using a typical antipsychotic. </p> </section> <section id="CD009005-sec-0183"> <h4 class="title">1.33 Adverse events: 2. Movement disorders ‐ b.ii. change scores (SAS, high = bad)</h4> <p>We found one trial (N = 63) who only reported change data for the SAS scale, which also did not showed any difference between the two intervention groups (<a href="./references#CD009005-fig-0036" title="">Analysis 1.33</a>). </p> </section> <section id="CD009005-sec-0184"> <h4 class="title">1.34 Adverse events: 2. Movement disorders ‐ b.iii. average scores (TESS, high = bad)</h4> <p>Again, three out of the five trials that reported movement disorders on the TESS reported skewed data. Heterogeneity was very high for the other two trials (I² = 99%) and so they were not pooled. Similarly to the findings on the SAS, the trial (<a href="./references#CD009005-bbs2-0035" title="ChaC , HuiG , QuingG . Evaluation of therapeutic effect with chlorpromazine and clozapine for treatment of schizophrenia. Xinxiang Med Stud1999;16:311‐6. ">C +CPZ 1999</a>) using a typical antipsychotic resulted in worse movement disorders for the combination group (MD 5.80 CI 5.03 to 6.57; <a href="./references#CD009005-fig-0037" title="">Analysis 1.34</a>); the trial with other atypical drugs showed no difference between monotherapy and combination. </p> </section> <section id="CD009005-sec-0185"> <h4 class="title">1.35 Adverse events: 2. Movement disorders ‐ b.iv. average scores (DIEPSS, high = bad) </h4> <p>One trial (<a href="./references#CD009005-bbs2-0020" title="ChangJS , AhnYM , ParkHJ , LeeKY , KimSH , KangUG , et al. Aripiprazole augmentation in clozapine‐treated patients with refractory schizophrenia: an 8‐week, randomized, double‐blind, placebo‐controlled trial. Asian Psychiatric Educational Workshop2007;5:720‐31. [MEDLINE: Chang 2008] ChangJS , AhnYM , ParkHJ , LeeKY , KimSH , KangUG , et al. Aripiprazole augmentation in clozapine‐treated patients with refractory schizophrenia: an 8‐week, randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2008;69(5):720‐31. [1555‐2101: (Electronic); MEDLINE: Kim 2006 g2] ChangJS , LeeNY , AhnYM , KimYS . The sustained effects of aripiprazole‐augmented clozapine treatment on the psychotic systems and metabolic profiles of patients with refractory schizophrenia. Journal of Clinical Psychopharmacology2012;32(2):282‐4. [DOI: 10.1097/JCP.0b013e3182485871] KimYS . A double‐blind randomized placebo controlled study of aripiprazole augmentation for clozapine‐treated patients with refractory schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00328367?term=NCT00328367&amp;rank=1 (first received 17 May 2006). [MEDLINE: Kim 2006 g] ">C +aripiprazole 2008</a>), with a follow‐up duration of eight weeks, which tested clozapine in both the combination and monotherapy groups, found no important difference in movement disorders when measured on the DIEPSS scale (MD 0.30 CI ‐0.49 to 1.09; participants = 61; studies = 1; <a href="./references#CD009005-fig-0038" title="">Analysis 1.35</a>). </p> </section> <section id="CD009005-sec-0186"> <h4 class="title">1.36 Adverse events: 2. Movement disorders ‐ b.v. change scores (BAS, high = bad)</h4> <p>Ten trials reported on movement disorders using the BAS, but in eight, data were very skewed and were not added to the analysis. Two trials, with follow‐up duration of six weeks, which tested atypical antipsychotics in both the combination and monotherapy groups, found no significant difference in movement disorders when measured on the BAS scale (MD ‐0.70 CI ‐1.54 to 0.14; N = 91; studies = 2; <a href="./references#CD009005-fig-0039" title="">Analysis 1.36</a>). <a href="./references#CD009005-bbs2-0028" title="RaghuthamanG , VenkateswaranR , KrishnadasR . Adjunctive aripiprazole in risperidone‐induced hyperprolactinaemia: double‐blind, randomised, placebo‐controlled trial. British Journal of Psychiatry Open2015;1(2):172‐7. [DOI: 10.1192/bjpo.bp.115.001248] ">C +aripiprazole 2015b</a> reported that all participants scored zero at follow‐up. </p> </section> <section id="CD009005-sec-0187"> <h4 class="title">1.37 Adverse events: 2. Movement disorders ‐ b.vi. change scores (AIMS, high = bad)</h4> <p>Five trials reported on movement disorders using the AIMS, but in four studies data were very skewed and not added to the analysis. One trial (N = 63), with follow‐up duration of six weeks, which tested atypical antipsychotics in both the combination and monotherapy groups, found no significant difference in movement disorders when measured on the AIMS scale (MD 0.10 CI ‐0.84 to 1.04; <a href="./references#CD009005-fig-0040" title="">Analysis 1.37</a>). </p> </section> <section id="CD009005-sec-0188"> <h4 class="title">1.38 Adverse events: 3. Endocrine ‐ prolactin level (high = bad)</h4> <p>Fifteen trials reported prolactin levels, but in eight, data were very skewed and not added to the analysis. In the seven remaining trials with six to 16 weeks follow‐up, the pooled data regarding change in prolactin level had very high heterogeneity (I² = 98%, <a href="./references#CD009005-fig-0041" title="">Analysis 1.38</a>). For studies with clozapine in both groups, data were also highly heterogeneous (I² = 98%). When we split the data by trials using aripiprazole as the add‐on antipsychotic, the heterogeneity is reduced (I² = 66%) for the trials not using aripiprazole as an intervention. Data were not pooled for this outcome. </p> </section> <section id="CD009005-sec-0189"> <h4 class="title">1.39 Adverse events: 4. Metabolic ‐ a. weight gain (binary)</h4> <p>Six trials (N = 804), with six to 16 weeks follow‐up, provided data regarding the number of participants experiencing weight gain. No significant difference was found in the number of participants experiencing weight gain (RR 1.00 CI 0.66 to 1.53; <a href="./references#CD009005-fig-0042" title="">Analysis 1.39</a>). </p> </section> <section id="CD009005-sec-0190"> <h4 class="title">1.40 Adverse events: 4. Metabolic ‐ b. average weight gain (kg)</h4> <p>Nine trials, with six to 16 weeks follow‐up, provided data regarding average weight gain, but results showed high heterogeneity (I² = 53%; <a href="./references#CD009005-fig-0043" title="">Analysis 1.40</a>). When <a href="./references#CD009005-bbs2-0009" title="FleischhackerWW , HeikkinenME , OlieJP , LandsbergW , DewaeleP , McQuadeRD , et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine:a randomized, double‐blind, placebo‐controlled trial. International Journal of Neuropsychopharmacology2010;13(8):1115‐25. [DOI: 10.1017/S1461145710000490] FleischhackerWW , HeikkinenME , OliéJP , LandsbergW , DewaeleP , McQuadeR , et al. Weight change on aripiprazole‐clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16‐week double‐blind study. European Psychiatry2008;23(Suppl 2):114‐5. [DOI: 10.1016/j.eurpsy.2008.01.784; 0924‐9338] KrielW . A multicenter, comparative, randomized, double‐blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. www.sanctr.gov.za/SAClinicalTrials/tabid/169/Default.aspx (first received 15 November 2006). MillarH , FelterC , LandsbergW . The effects of aripiprazole in combination with clozapine: patient functioning results from a double‐blind, 16‐week study in patients with schizophrenia (CN138‐170). Journal of Psychopharmacology2008;22(5):A17. [MEDLINE: Millar 2008 a] ">B +aripiprazole 2008</a> is removed from the analysis, the heterogeneity is reduced (I² = 4%), but as this trial carries more than 10% of the weighting for this outcome, the results were not pooled. </p> </section> <section id="CD009005-sec-0191"> <h4 class="title">1.41 Adverse events: 5. Blood ‐ a. decreased white cell counts (binary)</h4> <p>Two trials (N = 315), tested clozapine in both groups with eight to 12 weeks follow‐up provided data regarding number of participants experiencing decreased white cell counts. A significant difference was found in favour of the combination therapy (RR 0.18 CI 0.04 to 0.82; <a href="./references#CD009005-fig-0044" title="">Analysis 1.41</a>). The result could be explained by a dose‐dependant side effect. The studies used higher doses in the clozapine monotherapy group when compared with the doses used in the combination group. </p> </section> <section id="CD009005-sec-0192"> <h4 class="title">1.42 Adverse events: 5. Blood ‐ b. average white cell counts (10‐3/mm3)</h4> <p>One trial (N = 61) with eight weeks follow‐up reported data for white blood cell counts. No significant difference was found between the monotherapy and combination groups (MD 0.66 CI ‐ 0.20 to 1.52; <a href="./references#CD009005-fig-0045" title="">Analysis 1.42</a>). A further four trials measured white blood counts but did not report any data: <a href="./references#CD009005-bbs2-0020" title="ChangJS , AhnYM , ParkHJ , LeeKY , KimSH , KangUG , et al. Aripiprazole augmentation in clozapine‐treated patients with refractory schizophrenia: an 8‐week, randomized, double‐blind, placebo‐controlled trial. Asian Psychiatric Educational Workshop2007;5:720‐31. [MEDLINE: Chang 2008] ChangJS , AhnYM , ParkHJ , LeeKY , KimSH , KangUG , et al. Aripiprazole augmentation in clozapine‐treated patients with refractory schizophrenia: an 8‐week, randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2008;69(5):720‐31. [1555‐2101: (Electronic); MEDLINE: Kim 2006 g2] ChangJS , LeeNY , AhnYM , KimYS . The sustained effects of aripiprazole‐augmented clozapine treatment on the psychotic systems and metabolic profiles of patients with refractory schizophrenia. Journal of Clinical Psychopharmacology2012;32(2):282‐4. [DOI: 10.1097/JCP.0b013e3182485871] KimYS . A double‐blind randomized placebo controlled study of aripiprazole augmentation for clozapine‐treated patients with refractory schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00328367?term=NCT00328367&amp;rank=1 (first received 17 May 2006). [MEDLINE: Kim 2006 g] ">C +aripiprazole 2008</a> also found no difference between groups, <a href="./references#CD009005-bbs2-0051" title="JosiassenRC , JosephA , KohegyiE , StokesS , DadvandM , PaingWW , et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐controlled trial. 9th International Congress on Schizophrenia Research; 2003 Mar 29‐Apr 2; Colorado Springs, CO. 2003:130‐6. [MEDLINE: Josiassen 2003] JosiassenRC , JosephA , KohegyiE , StokesS , DadvandM , PaingWW , et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry2005;162(1):130‐6. [0002‐953X: (Print); DOI: 10.1176/appi.ajp.162.1.130; MEDLINE: Josiassen 2005] ">C +risperidone 2005b</a> and <a href="./references#CD009005-bbs2-0055" title="ShilohR , ZemishlanyZ , AizenbergD , RadwanM , SchwartzB , Dorfman‐EtrogP , et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double‐blind, placebo‐controlled study. British Journal of Psychiatry1997;171:569‐73. [0007‐1250: (Print); Shiloh 1997] ShilohR , ZemishlanyZ , AizenbergD , WeizmanA . Sulpiride adjunction to clozapine in treatment‐resistant schizophrenic patients: a preliminary case series study. European Psychiatry1997;12(3):152‐5. [0924‐9338: (Print); MEDLINE: Shiloh 1997] ">C +sulpiride 1997</a> reported that there were no changes in white blood cell counts. </p> </section> <section id="CD009005-sec-0193"> <h4 class="title">1.43 Adverse events: 6. Central nervous system (CNS) ‐ a. drowsiness</h4> <p>Eleven trials, with six to 16 weeks follow‐up, provided data regarding drowsiness, but results showed high heterogeneity (I² = 67%; <a href="./references#CD009005-fig-0046" title="">Analysis 1.43</a>). When the outlying trials <a href="./references#CD009005-bbs2-0047" title="NiJ , JangL , HongX . Therapeutic effects of clozapine, risperidone and their combination in the treatment of schizophrenia. Health Psychology2001;3:181‐2. ">C +risperidone 2001</a> and <a href="./references#CD009005-bbs2-0054" title="NielsenJ , EmborgC , GydesenS , DybbroJ , AagaardJ , HaderupK , et al. Augmenting clozapine with sertindole: a double‐blind, randomized, placebo‐controlled study. Journal Clincal Psychopharmacology2012;32(2):173‐8. [DOI: 10.1097/JCP.0b013e318248dfb8] NielsenJ , Munk‐JorgensenP . Augmenting clozapine with sertindole ‐ a double blinded randomized placebo study. www.clinicaltrials.gov/ct2/show/NCT00345982?term=NCT00345982&amp;rank=1 (first received 28 June 2006). [Nielsen 2006] NielsenRE , LevanderS , ThodeD , NielsenJ . Effects of sertindole on cognition in clozapine‐treated schizophrenia patients. Acta Psychiatrica Scandinavica2012;126(1):31‐9. [DOI: 10.1111/j.1600‐0447.2012.01840.x] ">C +sertindole 2006</a> are removed from the analysis heterogeneity restores both for the clozapine group and overall. As these trials carry more than 10% of the weighting for this outcome, the results were not pooled. </p> </section> <section id="CD009005-sec-0194"> <h4 class="title">1.44 Adverse events: 6. Central nervous system (CNS) ‐ b. tremor</h4> <p>Four trials (N = 22), with six to 12 weeks follow‐up, found no significant difference in the number of patients in the monotherapy or combination therapy groups experiencing tremors (RR 0.87 CI 0.47 to 1.62; <a href="./references#CD009005-fig-0047" title="">Analysis 1.44</a>) </p> </section> <section id="CD009005-sec-0195"> <h4 class="title">1.45 Quality of life: 1a. Average score (QLS high=good)</h4> <p><a href="./references#CD009005-bbs2-0050" title="AkdedeBB , Anil YagciogluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. [1555‐2101: (Electronic); DOI: 10.4088/JCP.v67n1211; MEDLINE: Anil Yagcioglu 2005] AnilE . Risperidone augmented with clozapine for schizophrenia. Stanley Foundation Research Programs2009. [MEDLINE: Anil Yagcioglu 2005] Anil YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005; Vol. 66, issue 1:63‐72. [0160‐6689: (Print); DOI: 10.4088/JCP.v66n0109; MEDLINE: Anil Yagcioglu 2005] YagciogluAEA , AkdedeBBK , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. 24th Congress of the Collegium Internationale Neuro‐Psychopharmacologicum (CINP); 2004 Jun 20‐24; Paris, France. 2004:63‐72. [MEDLINE: Yagcioglu 2004] ">C +risperidone 2005</a> with 30 participants and a follow‐up of six weeks, tested clozapine in both groups. This trial measured quality of life on the QLS scale and found no important difference between treatment groups (MD 0.80 CI ‐5.44 to 7.04; <a href="./references#CD009005-fig-0048" title="">Analysis 1.45</a>). </p> </section> <section id="CD009005-sec-0196"> <h4 class="title">1.46 Quality of life: 1b. Average score (SWN, high=good)</h4> <p>Two trials with eight to 16 weeks follow‐up, which tested clozapine in both groups measured quality of life on the SWN scale and found no significant difference between treatment groups (MD 2.05 CI ‐1.08 to 5.18; <a href="./references#CD009005-fig-0049" title="">Analysis 1.46</a>). <a href="./references#CD009005-bbs2-0012" title="KaneJM , CorrellCU , GoffDC , KirkpatrickB , MarderSR , Vester‐BloklandE , et al. A multicenter, randomized, double‐blind, placebo‐controlled, 16‐week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry2009;70(10):1348‐57. [1555‐2101: (Electronic); DOI: 10.4088/JCP.09m05154yel; Kane 2009] NCT00325689 . A multicenter, randomized, double‐blind, placebo‐controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder.. www.clinicaltrials.gov/ct2/show/NCT00325689?term=NCT00325689&amp;rank=1 (first received May 11 2006). [MEDLINE: Bristol‐Myers 2006] ">B +quet/risp 2009</a> also used the SWN scale, but did not report SDs and no suitable means were available to impute the data. </p> </section> <section id="CD009005-sec-0197"> <h4 class="title">1.47 Quality of Life: 1c. Average score ‐ Mental component summary (SF‐36, high = good) </h4> <p><a href="./references#CD009005-bbs2-0062" title="LinCH , WangFC , LinSC , HuangYH , ChenCC , LaneHY . Antipsychotic combination using low‐dose antipsychotics is as efficacious and safe as, but cheaper, than optimal‐dose monotherapy in the treatment of schizophrenia: a randomized, double‐blind study. International Clinical Psychopharmacology2013;28(5):267‐74. [DOI: 10.1097/YIC.0b013e3283633a83.] ">C +sulpiride 2013</a> (N = 60) with a follow‐up of six weeks, measured the mental component of quality of life on the SF‐36 scale and found no significant difference between treatment groups (MD 0.60 CI ‐4.28 to 5.48; <a href="./references#CD009005-fig-0050" title="">Analysis 1.47</a>). </p> </section> <section id="CD009005-sec-0198"> <h4 class="title">1.48 Quality of Life: 1d. Average score ‐ Physical component summary (SF‐36, high = good) </h4> <p>Again, <a href="./references#CD009005-bbs2-0062" title="LinCH , WangFC , LinSC , HuangYH , ChenCC , LaneHY . Antipsychotic combination using low‐dose antipsychotics is as efficacious and safe as, but cheaper, than optimal‐dose monotherapy in the treatment of schizophrenia: a randomized, double‐blind study. International Clinical Psychopharmacology2013;28(5):267‐74. [DOI: 10.1097/YIC.0b013e3283633a83.] ">C +sulpiride 2013</a> (N = 60) with a follow‐up of six weeks, measured the physical component of quality of life on the SF‐36 scale and found no significant difference between treatment groups (MD ‐1.70 CI ‐4.71 to 1.31). </p> </section> <section id="CD009005-sec-0199"> <h4 class="title">2. Other outcomes</h4> <p>Although <a href="./references#CD009005-bbs2-0005" title="BarrettWW , EllsworthRB , ClarkLD , EnnissJ . Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients. Diseases of the Nervous System1957; Vol. 18, issue 6:209‐15. [0012‐3714: (Print); Barrett 1957] ">A +reserpine 1957</a>, <a href="./references#CD009005-bbs2-0008" title="HoriH , YoshimuraR , KatsukiA , SugitaAI , AtakeK , NakamuraJ . Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of Psychiatric Research2013;47(12):1843‐8. [DOI: 10.1016/j.jpsychires.2013.08.024] ">B +any antipsychotic 2013</a>, <a href="./references#CD009005-bbs2-0033" title="ChienCP , ColeJO . Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. American Journal of Psychiatry1973;130(1):13‐8. [0002‐953X: (Print); DOI: 10.1176/ajp.130.1.13; MEDLINE: Chien 1973] ">C +CPZ 1973</a> and <a href="./references#CD009005-bbs2-0044" title="BergmannM , GolemboS , FriedmanJI , Trammel‐FisherA , SieverLJ . Pimozide augmentation of clozapine in schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00158223?term=NCT00158223&amp;rank=1 (first received 7 September 2005). [MEDLINE: Bergmann 2005] FriedmanJI , LindenmayerJP , AlcantaraF , BowlerS , ParakM , WhiteL , et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology2011;36(6):1289‐95. [DOI: 10.1038/npp.2011.14] ">C +pimozide 2011</a> measured behaviour and social functioning (on four different scales), none reported data that could be used in the analysis. Data were also not available on number of days in hospital, change in hospital status, employment status during trial, occurrence of violent incidents, levels of substance abuse, adverse events requiring hospitalisation, and allergic reactions. Studies did not report economic burden (cost of care), although two trials reported the cost of the therapies; <a href="./references#CD009005-bbs2-0038" title="LinCH , KuoCC , ChouLS , ChenYH , ChenCC , HuangKH , et al. A randomized, double‐blind comparison of risperidone versus low‐dose risperidone plus low‐dose haloperidol in treating schizophrenia. Journal of Clinical Psychopharmacology2010;30(5):518‐25. [DOI: 10.1097/JCP.0b013e3181f28dff] ">C +haloperidol 2010</a> reported the cost of the combination therapy (2mg per day risperidone plus 2 mg per day haloperidol, $1.26 per day) was approximately half the cost of the monotherapy (4 mg per day risperidone, $2.40) and <a href="./references#CD009005-bbs2-0062" title="LinCH , WangFC , LinSC , HuangYH , ChenCC , LaneHY . Antipsychotic combination using low‐dose antipsychotics is as efficacious and safe as, but cheaper, than optimal‐dose monotherapy in the treatment of schizophrenia: a randomized, double‐blind study. International Clinical Psychopharmacology2013;28(5):267‐74. [DOI: 10.1097/YIC.0b013e3283633a83.] ">C +sulpiride 2013</a> reported the cost of the combination therapy (amisulpride 400 mg per/day plus sulpiride 800 mg/day, US$2.82/day) was also approximately half of the cost of monotherapy (amisulpride 800 mg/day, $4.88/day). </p> </section> <section id="CD009005-sec-0200"> <h4 class="title">3. Subgroup analyses for clinical response: not clinically improved</h4> <p>We used random‐effects model for subgroup analyses. No subgroup differences were found for clinical response for subgroup analyses of chronic versus acutely ill people, length of treatment less than 12 weeks versus more than 12 weeks and between studies that tested clozapine in both groups versus all other studies (<a href="./references#CD009005-fig-0052" title="">Analysis 1.49</a>; <a href="./references#CD009005-fig-0053" title="">Analysis 1.50</a>; <a href="./references#CD009005-fig-0054" title="">Analysis 1.51</a>). A subgroup difference was found between the drugs added to clozapine (P = 0.009; <a href="./references#CD009005-fig-0055" title="">Analysis 1.52</a>) with pipotiazine and sulpiride favouring the combination of antipsychotics and risperidone showing no differences in the number of participants not clinically improved. The pooled results showed high heterogeneity (I² = 64%). However, when the risperidone subgroup is removed heterogeneity is restored. </p> <p>In the meta‐regression, we did not found an effect or an interaction by the potential modifiers: year of publication and Chinesse origin. The meta‐regression model adjust was poor (0.00%) (<a href="#CD009005-tbl-0002">Table 1</a>). </p> <div class="table" id="CD009005-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐regression</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Estimate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>SE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Upper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐29.5401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.5608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐81.5983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.5181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2661</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.0114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2706</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chinese</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.7592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120.7041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐171.8166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301.3349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5916</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year*Chinese (interaction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.0326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.1508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5895</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>tau² (estimated amount of residual heterogeneity): 0.8884 (SE = 0.4106)</p> <p>tau (square root of estimated tau² value): 0.9426</p> <p>I² (residual heterogeneity / unaccounted variability): 97.91%</p> <p>H² (unaccounted variability / sampling variability): 47.80%</p> <p>R² (amount of heterogeneity accounted for): 0.00%</p> </div> </div> </section> <section id="CD009005-sec-0201"> <h4 class="title">4. Subgroup analyses for leaving the study early</h4> <p>No subgroup differences were found for leaving the study early for the subgroup analyses of chronic versus acutely ill people, length of treatment less than 12 weeks versus more than 12 weeks, between studies that tested clozapine in both groups versus all other studies and between the drugs added to clozapine (<a href="./references#CD009005-fig-0056" title="">Analysis 1.53</a>; <a href="./references#CD009005-fig-0057" title="">Analysis 1.54</a>; <a href="./references#CD009005-fig-0058" title="">Analysis 1.55</a>; <a href="./references#CD009005-fig-0059" title="">Analysis 1.56</a>). </p> </section> <section id="CD009005-sec-0202"> <h4 class="title">5. Sensitivity analyses for clinical response: not clinically improved</h4> <p>Three studies (<a href="./references#CD009005-bbs2-0014" title="LiuQH , LiXL , ZhangYQ , JinSL , LiZC , WangNS , et al. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chinese Journal of Psychiatry1996;29(2):87‐90. [MEDLINE: Liu 1996] ">B +sulpiride 1996</a>; <a href="./references#CD009005-bbs2-0056" title="SiS , YuanC . A comparative trial of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry1999;12:17‐20. ">C +sulpiride 1999</a>; <a href="./references#CD009005-bbs2-0057" title="XaoH . A double‐blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Mental Health1999;12:250‐1. ">C +sulpiride 1999b</a>) which reported data for clinical response had a high risk of bias for sequence generation. A significant subgroup difference (P = 0.03; <a href="./references#CD009005-fig-0060" title="">Analysis 1.57</a>) was found between studies with a low or unclear risk of bias versus those with a high risk of bias for randomisation, with both groups favouring the combination of antipsychotics. No subgroup difference was found between studies with a low or unclear risk of bias versus those with a high risk of bias for blinding (<a href="./references#CD009005-fig-0060" title="">Analysis 1.57</a>). When data are synthesised using a fixed‐effect model, results remain unchanged (RR 0.74 CI 0.68 to 0.81; <a href="./references#CD009005-fig-0062" title="">Analysis 1.59</a>). </p> </section> <section id="CD009005-sec-0203"> <h4 class="title">6. Sensitivity analyses for leaving the study early</h4> <p>Only one study that reported data for leaving the study early had a high risk of bias for sequence generation (<a href="./references#CD009005-bbs2-0036" title="ShaftiSS . Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses2009;3(2):97‐102. [DOI: 10.3371/CSRP.3.2.4] ">C +fluphen dec 2009</a>). This small study reported no losses to follow‐up and so no sensitivity analysis was possible (<a href="./references#CD009005-fig-0063" title="">Analysis 1.60</a>). No subgroup difference was found between studies with a low or unclear risk of bias versus those with a high risk of bias for blinding (<a href="./references#CD009005-fig-0064" title="">Analysis 1.61</a>). When data for is synthesised using a fixed‐effect model the results remain unchanged (RR 0.87, 95% CI 0.76 to 1.00, <a href="./references#CD009005-fig-0065" title="">Analysis 1.62</a>) except for studies that tested typical drugs in both groups and any antipsychotic in both groups in which the combination therapy was favoured. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009005-sec-0204" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009005-sec-0204"></div> <section id="CD009005-sec-0205"> <h3 class="title" id="CD009005-sec-0205">Summary of main results</h3> <p>The summary below reflects the outcomes chosen for the 'Summary of findings' table, and considers the main findings of this review that can support evidence‐based decision making. For all outcomes included in the 'Summary of findings' table the quality of evidence was found to be either low or very low. Overall, findings from this review are that combination therapy does not have clear differences in its effects compared with monotherapy. </p> <section id="CD009005-sec-0206"> <h4 class="title">1. Clinical response: not clinically improved</h4> <p>Overall, we found evidence that combination therapy may be superior to monotherapy in improving clinical response. Subgroup analyses of different combinations of antipsychotics showed that this effect was due to the trials who included either clozapine in both groups or atypical drugs in both groups. It is important to note that these findings are mostly from short‐term trials (22 trials of 12 weeks or less). Only two long‐term trials (one year and three years) were identified. We, therefore, do not know what the efficacy might be if more trials had measured this outcome in the long term. Also, the definition of clinical response varied considerably across the studies hindering the interpretation of the findings. The finding that typical drugs in both groups may improve clinical response should be taken with caution, as all of the studies were undertaken more than 30 years ago, and translating these data to the actual clinical setting may be problematic. Nonetheless, the finding that adjunctive antipsychotic drug to either clozapine or a typical antipsychotics remains an interesting finding and worth considering to be the focus of further work. The very low quality of the evidence, as assessed with GRADE, diminish the confidence that can be placed in the magnitude of the effect. </p> </section> <section id="CD009005-sec-0207"> <h4 class="title">2. Clinical response: relapse</h4> <p>There was a lack of information within the studies regarding relapse, most likely due to the duration of the trials (see above), and failure to report this outcome in the trials that were longer. Only three studies reported relapse ‐ two of which were older studies comparing typical antipsychotics in both groups (<a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a>; <a href="./references#CD009005-bbs2-0043" title="YagiG . A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation1976; Vol. 3:351‐403. [MEDLINE: Yagi 1976] ">C +perphenazine 1976</a>) and one, a more recent trial, testing clozapine in both groups (<a href="./references#CD009005-bbs2-0006" title="WangCH , QinTF , LinYL , ZhaoXF . A clinical effect and following‐up study about sulpiride and clozapine for 105 cases of the schizophrenia type. Journal of Xinxiang Medical College1994;11(2):148‐51. [MK_007527] ">A +sulpiride 1994</a>). There was a lot of heterogeneity for this outcome, perhaps unsurprisingly given such different treatment drugs and lengths of trials: <a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a> showed an important efficacy in favour of the combination treatment group for typical drugs over one year, and <a href="./references#CD009005-bbs2-0043" title="YagiG . A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation1976; Vol. 3:351‐403. [MEDLINE: Yagi 1976] ">C +perphenazine 1976</a> showed no difference over the course of eight weeks. <a href="./references#CD009005-bbs2-0006" title="WangCH , QinTF , LinYL , ZhaoXF . A clinical effect and following‐up study about sulpiride and clozapine for 105 cases of the schizophrenia type. Journal of Xinxiang Medical College1994;11(2):148‐51. [MK_007527] ">A +sulpiride 1994</a>, however, showed no difference over three years for clozapine in both groups. Currently, there is only sparse evidence on relapse for typical antipsychotic combination therapy and clozapine combination therapy, and oddly, a complete lack of evidence regarding other atypical drugs in combination. </p> </section> <section id="CD009005-sec-0208"> <h4 class="title">3. Leaving the study early</h4> <p>In 43 RCTs between 0% and 74% (average ˜ 16%) of people receiving antipsychotics (combination or monotherapy) left the study early. Overall, there was not convincing evidence that, at least within trials, combined antipsychotic treatment was any different to monotherapy for helping people stay longer. People do leave early for a variety of reasons, but the combination therapies did not clearly prevent or encourage this. A common precursor to relapse is stopping medication. Combining antipsychotics does not seem to prevent or encourage cessation, although generalising from these studies to the real world is problematic. Nine studies ‐ four with clozapine in both groups (<a href="./references#CD009005-bbs2-0051" title="JosiassenRC , JosephA , KohegyiE , StokesS , DadvandM , PaingWW , et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐controlled trial. 9th International Congress on Schizophrenia Research; 2003 Mar 29‐Apr 2; Colorado Springs, CO. 2003:130‐6. [MEDLINE: Josiassen 2003] JosiassenRC , JosephA , KohegyiE , StokesS , DadvandM , PaingWW , et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry2005;162(1):130‐6. [0002‐953X: (Print); DOI: 10.1176/appi.ajp.162.1.130; MEDLINE: Josiassen 2005] ">C +risperidone 2005b</a>; <a href="./references#CD009005-bbs2-0048" title="PengH , KuangY , HuangX . A control study of risperidone in combination with clozapine in treating refractory schizophrenia. Journal of Modern Clinical Medical Bioengineering2001;7(2):100‐2. [MEDLINE: Peng 2001] ">C +risperidone 2001b</a>; <a href="./references#CD009005-bbs2-0055" title="ShilohR , ZemishlanyZ , AizenbergD , RadwanM , SchwartzB , Dorfman‐EtrogP , et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double‐blind, placebo‐controlled study. British Journal of Psychiatry1997;171:569‐73. [0007‐1250: (Print); Shiloh 1997] ShilohR , ZemishlanyZ , AizenbergD , WeizmanA . Sulpiride adjunction to clozapine in treatment‐resistant schizophrenic patients: a preliminary case series study. European Psychiatry1997;12(3):152‐5. [0924‐9338: (Print); MEDLINE: Shiloh 1997] ">C +sulpiride 1997</a>; <a href="./references#CD009005-bbs2-0058" title="ZhuY , ZhangS , ZhangD . A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. Journal of Clinical Psychology in Medical Settings1999;9(4):204‐5. [MEDLINE: Zhu 1999] ">C +sulpiride 1999c</a>), four with other atypical drugs in both groups (<a href="./references#CD009005-bbs2-0017" title="MayabhateM , BadarV , SomaniA . Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double‐blind placebo controlled clinical study. International Journal of Basic and Clinical Pharmacology2014;3(1):130‐8. [DOI: 10.5455/2319‐2003.ijbcp20140216] ">C +arip/pali 2014</a>; <a href="./references#CD009005-bbs2-0031" title="XieC , NiXL . The compared study of treating schizophrenia with risperidone combining clozapine. Journal of Preventative Medicine2001;17(4):245. [MEDLINE: Xie 2001] ">C +clozapine 2001</a>; <a href="./references#CD009005-bbs2-0032" title="JiangL , LeiJ , PengL , et al. Analysis of efficacy of antipsychotics combined with clozapine orally disintegrating tablets in the treatment of schizophrenia with negative symptoms [氯氮平联合抗精神病药治疗精神分裂症阴性 症状的效果分析]. Journal of Bethune Military Medical College2013;11(4):310‐11. ">C +clozapine 2013</a>; <a href="./references#CD009005-bbs2-0036" title="ShaftiSS . Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses2009;3(2):97‐102. [DOI: 10.3371/CSRP.3.2.4] ">C +fluphen dec 2009</a>), and one with typical drugs in both groups (<a href="./references#CD009005-bbs2-0007" title="TalbotDR . Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry1964;121:597‐600. [0002‐953X: (Print); MEDLINE: Talbot 1964] ">A +trifluoperazine 1964</a>) ‐ had no participants leave early at all and were therefore not accounted for in the general analysis. </p> </section> <section id="CD009005-sec-0209"> <h4 class="title">4. Hospital admission</h4> <p>There was a lack of studies contributing to this outcome, most likely attributed to the setting of the trials as most were performed in an inpatient setting. Of the three included trials only one was long term (<a href="./references#CD009005-bbs2-0001" title="EssockSM , SchoolerNR , StroupTS , McEvoyJP , RojasI , JacksonC , et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry2011;168(7):702‐8. [DOI: 10.1176/appi.ajp.2011.10060908] ">A +any antipsychotic 2011</a>) and contributed to 80.7% of the weight for this outcome. No difference was found between treatment groups in the number of participants hospitalised. </p> </section> <section id="CD009005-sec-0210"> <h4 class="title">5. Adverse events</h4> <p>We did not find evidence of a difference between treatment groups in serious adverse events or those requiring discontinuation; neither subgroup analysis showed a significant difference. There were no reports of agranulocytosis. Although there were no differences in serious adverse events in the short term, we are not able to say whether there is a difference in serious adverse events when using these therapies in the long term as most of the data is from short‐term trials (22 trials of 12 weeks or less). Nine studies had no serious adverse events or an event requiring discontinuation at all and were therefore not accounted for in this general analysis. There was no evidence of a difference in the number of patients experiencing movement disorders or weight gain. </p> </section> <section id="CD009005-sec-0211"> <h4 class="title">5. Quality of life</h4> <p>There is a lack of evidence on quality of life, with only four studies reporting data for this outcome on three different scales, none of which showed a difference between treatment groups. </p> </section> </section> <section id="CD009005-sec-0212"> <h3 class="title" id="CD009005-sec-0212">Overall completeness and applicability of evidence</h3> <section id="CD009005-sec-0213"> <h4 class="title">1. Completeness</h4> <p>We did not find any trials with data for the following outcomes: days in hospital, change in hospital status, general behaviour, specific behaviours, social functioning, employment status during the trial, occurrence of violent incidents, and level of substance abuse. Quality of life, independence and the ability to work are important outcomes for those living with schizophrenia. Very few studies reported data for these outcomes and, those that did, reported data that are not really clinically meaningful. </p> <p>We are aware of one study (<a href="./references#CD009005-bbs2-0125" title="NCT01450514 . Proof‐of‐concept study of pipamperone 15mg added to stable risperidone or paliperidone treatment in chronic schizophrenic and schizoaffective patients with residual symptoms: a Phase I/IIa, randomized, double‐blind, placebo‐controlled trial of 7 weeks. clinicaltrials.gov/show/NCT01450514 (first received 7 October 2011). ">NCT01450514</a>) that looked at the effects of a combination therapy versus monotherapy. We tried to obtain data from this trial but the sponsor decided not to provide data as they wanted to keep it confidential. </p> <p>For studies that had both clozapine and another antipsychotic in two monotherapy groups, we only included the data from the clozapine arm, as we considered this to be the more important comparison and in order to facilitate subgroup analyses. </p> <p>This review compares only monotherapy with combination therapy, and we do not make direct comparisons between different types of combinations of antipsychotics, e.g. combinations including typical antipsychotics versus those containing clozapine. </p> </section> <section id="CD009005-sec-0214"> <h4 class="title">2. Applicability</h4> <p>The majority of studies were less than 12 weeks in duration, with 10 trials longer or equal to six months and, as schizophrenia is a chronic disease with a long‐term course, there is only limited information about the long‐term safety and efficacy of antipsychotic combination therapy. Most trials were undertaken in very formalised settings ‐ not at all reflective of the everyday circumstances in which people with schizophrenia live. This must also reduce applicability. Long trials set in very real‐world circumstances are needed. </p> </section> </section> <section id="CD009005-sec-0215"> <h3 class="title" id="CD009005-sec-0215">Quality of the evidence</h3> <p>As can be seen graphically in <a href="#CD009005-fig-0001">Figure 1</a> we felt the risk of bias in the included studies to be moderate to high. The majority of trials had unclear allocation concealment, method of randomisation and blinding, and were not free of selective reporting. Only around half of the studies addressed incomplete data adequately and in most it was unclear if they were free from other biases. There is a real danger in unfairly judging studies of the past by today's standards. However, this may not be as unfair as it seems. For mental health there is some evidence that reporting of trials was as good if not better in the 1960s and 1970s than it was two decades later (<a href="./references#CD009005-bbs2-0131" title="AhmedI , SoaresKV , SeifasR , AdamsCE . Randomized controlled trials in Archives of General Psychiatry (1959‐1995): a prevalence study. Archives of General Psychiatry1998;55(8):754‐5. [PUBMED: 9707389] ">Ahmed 1998</a>). However, the <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> initiative was formalised in 1996 (<a href="./references#CD009005-bbs2-0139" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637‐9. [PUBMED: 8773637] ">Begg 1996</a>), and only eight of the 62 included trials predated this. That only 18 trials reported adequate generation and 16 the methods used to conceal allocation reflects poor quality reporting, probably poor [biased] conduct, and is certainly associated with exaggerated estimates of effect (<a href="./references#CD009005-bbs2-0189" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a>). </p> <p>The sensitivity analysis for the quality of reporting of randomisation did not suggest that the less convincingly randomised studies produced discernibly different results, nor did the sensitivity analysis for the blinding of studies. </p> </section> <section id="CD009005-sec-0216"> <h3 class="title" id="CD009005-sec-0216">Potential biases in the review process</h3> <p>In our search strategy we tried to identify all relevant trials. However, there is the possibility that we may have failed to identify some studies. We have worked only with published reports. By doing this we may be perpetuating a reporting and publishing bias. It would be better to have original individual patient data. </p> <p>The extraction of data and the risk of bias for the Chinese language studies were completed by only one review author. There is the possibility that this may have introduced some bias into the results as it was not possible to cross‐check these data. </p> </section> <section id="CD009005-sec-0217"> <h3 class="title" id="CD009005-sec-0217">Agreements and disagreements with other studies or reviews</h3> <p>We know of seven other reviews that compare various combinations of antipsychotics. <a href="./references#CD009005-bbs2-0145" title="CorrellCU , Rummel‐KlugeC , CorvesC , KaneJM , LeuchtS . Antipsychotic combinations vs monotherapy in schizophrenia: A meta‐analysis of randomized controlled trials. Schizophrenia Bulletin2009;35(2):443‐57. [DOI: 10.1093/schbul/sbn018] ">Correll 2009</a> addressed the same topic as the current review and reported that antipsychotic combination therapy was superior to monotherapy for inefficacy and leaving the study. In our analysis we also found an effect in favour of the combination therapy for inefficacy, but did not find a clear difference between treatments for leaving the study early. This difference in findings was due to our inclusion of more data from recently published studies. For example, for the outcome of 'leaving the study early', in <a href="./references#CD009005-bbs2-0145" title="CorrellCU , Rummel‐KlugeC , CorvesC , KaneJM , LeuchtS . Antipsychotic combinations vs monotherapy in schizophrenia: A meta‐analysis of randomized controlled trials. Schizophrenia Bulletin2009;35(2):443‐57. [DOI: 10.1093/schbul/sbn018] ">Correll 2009</a> the weighting for data from the trial <a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a> was 90%. For our review the weighting for these data from <a href="./references#CD009005-bbs2-0004" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom‐free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry1985;20(11):1161‐6. [0006‐3223: (Print); Nishikawa 1985] ">A +pimozide 1985</a> was only 12.6%. This illustrates how fast evidence can change with emergence of new data and the need for regular updating of review. </p> <p>The relevant Canadian Agency for Drugs and Technologies in Health overview (<a href="./references#CD009005-bbs2-0142" title="[No authorslisted] . Combination and high‐dose atypical antipsychotic therapy in patients with schizophrenia: systematic review. Canadian Agency for Drugs and Technologies in Health overviews2012;2(3):e2301. [PUBMED: 23002379] ">CADTH 2012</a>) presented results in subgroups for clozapine in both groups and other atypical drugs in both groups. Our findings were the same for efficacy, serious adverse events and leaving the study early. </p> <p>A further five reviews looked specifically at the augmentation of clozapine with another antipsychotic. <a href="./references#CD009005-bbs2-0137" title="BarberS , OlotuU , CorsiM , CiprianiA . Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD006324.pub3; CD006324] ">Barber 2017</a> included participants with treatment‐resistant schizophrenia and found efficacy in favour of the clozapine combination in open‐label studies but not double‐blind studies. This contrasts with our results, as in this review trials with a low or an unclear risk of bias for blinding favoured the combination of antipsychotics. <a href="./references#CD009005-bbs2-0192" title="SommerIE , BegemannMJ , TemmermanA , LeuchtS . Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin2012;38(5):1003‐11. [PUBMED: 21422107] ">Sommer 2012</a> reviewed pharmacological augmentation of clozapine. Our results did not differ from this review in regards to aripiprazole, haloperidol, risperidone and sulpiride augmentation. <a href="./references#CD009005-bbs2-0022" title="WangL , ZhangB , XuL , et al. A clinical study on aripiprazole in the treatment of female hyperprolactinemia by haloperidol. China Journal of Health Psychology2009;17(2):194‐5. ">C +aripiprazole 2009</a> reviewed sulpiride augmentation of clozapine and includes the same studies as our review, and the findings are the same. <a href="./references#CD009005-bbs2-0194" title="TaylorDM , SmithL . Augmentation of clozapine with a second antipsychotic‐‐a meta‐analysis of randomized, placebo‐controlled studies. Acta Psychiatrica Scandinavica2009;119(6):419‐25. [PUBMED: 19245679] ">Taylor 2009</a> also found efficacy in favour of combination therapy; however, they dealt with data differently from our review by combining data from the Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS), so it is not possible to compare the findings. They found no difference in leaving the study early, which is the same as our findings. <a href="./references#CD009005-bbs2-0183" title="MengM , LiW , ZhangS , WangHY , ShengJH , WangJ , et al. Using aripiprazole to reduce antipsychotic‐induced hyperprolactinemia: meta‐analysis of currently available randomized controlled trials. Shanghai Archives of Psychiatry2015;27(1):4‐17. [DOI: 10.11919/j.issn.1002‐0829.215014] ">Meng 2015</a> reviewed pharmacological augmentation with aripiprazole for participants with antipsychotic‐induced hyperprolactinaemia. They reported data differently from our review as they presented a dichotomous outcome for the proportion of participants whose prolactin levels returned to normal; their results favoured the use of aripiprazole. They also found no difference in leaving the study early. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009005-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009005-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009005-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Naming of the subgroups: The studies were arranged into four subgroups according to the type of antipsychotics used in both arms: clozapine, atypical antipsychotics other than clozapine, typical antipsychotics and any antipsychotics. Naming of the studies: The study tag starts with the duration category (A = long term (over 26 weeks); B = medium term (13 to 26 weeks) and C = short term (up to 12 weeks); the remainder of the tag is the additional drug in the combination antipsychotic group." data-id="CD009005-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Naming of the subgroups: The studies were arranged into four subgroups according to the type of antipsychotics used in both arms: clozapine, atypical antipsychotics other than clozapine, typical antipsychotics and any antipsychotics. Naming of the studies: The study tag starts with the duration category (A = long term (over 26 weeks); B = medium term (13 to 26 weeks) and C = short term (up to 12 weeks); the remainder of the tag is the additional drug in the combination antipsychotic group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 1 Clinical response: 1. No clinically important response ‐ not improved." data-id="CD009005-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 1 Clinical response: 1. No clinically important response ‐ not improved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 2 Clinical response: 2. Relapse." data-id="CD009005-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 2 Clinical response: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 3 Leaving the study early." data-id="CD009005-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 3 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 4 Service utilisation: Hospital admission." data-id="CD009005-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 4 Service utilisation: Hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 5 Clinical response: 3. Global state ‐ i. average severity score (CGI‐S scale, high = bad)." data-id="CD009005-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 5 Clinical response: 3. Global state ‐ i. average severity score (CGI‐S scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 6 Clinical response: 3. Global state ‐ ii. change in severity score (CGI‐S scale, high = bad)." data-id="CD009005-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 6 Clinical response: 3. Global state ‐ ii. change in severity score (CGI‐S scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 7 Clinical response: 4. Global state ‐ average improvement score (CGI‐I scale, high = bad)." data-id="CD009005-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 7 Clinical response: 4. Global state ‐ average improvement score (CGI‐I scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 8 Clinical response: 5. Global state ‐ i. average functioning score (GAF scale, high = good)." data-id="CD009005-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 8 Clinical response: 5. Global state ‐ i. average functioning score (GAF scale, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 9 Clinical response: 5. Global state ‐ ii. change in functioning score (GAF scale, high = good)." data-id="CD009005-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 9 Clinical response: 5. Global state ‐ ii. change in functioning score (GAF scale, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 10 Mental state: 1. Overall ‐ a.i average total score (PANSS scale, high = bad)." data-id="CD009005-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 10 Mental state: 1. Overall ‐ a.i average total score (PANSS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 11 Mental state: 1. Overall ‐ a.ii change in total score (PANSS scale, high = bad)." data-id="CD009005-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 11 Mental state: 1. Overall ‐ a.ii change in total score (PANSS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 12 Mental state: 1. Overall ‐ b.i. average total score (BPRS scale, high = bad)." data-id="CD009005-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 12 Mental state: 1. Overall ‐ b.i. average total score (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 13 Mental state: 1. Overall ‐ b.ii change total score (BPRS scale, high = bad)." data-id="CD009005-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 13 Mental state: 1. Overall ‐ b.ii change total score (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 14 Mental state: 2. Specific ‐ a. positive symptoms ‐ no clinical improvement." data-id="CD009005-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 14 Mental state: 2. Specific ‐ a. positive symptoms ‐ no clinical improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 15 Mental state: 2. Specific ‐ b. positive symptoms ‐ i. average score (PANSS scale, high = bad)." data-id="CD009005-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 15 Mental state: 2. Specific ‐ b. positive symptoms ‐ i. average score (PANSS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 16 Mental state: 2. Specific ‐ b. positive symptoms ‐ ii. change score (PANSS scale, high = bad)." data-id="CD009005-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 16 Mental state: 2. Specific ‐ b. positive symptoms ‐ ii. change score (PANSS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 17 Mental state: 2. Specific ‐ b. positive symptoms ‐ iii. average score (BPRS scale, high = bad)." data-id="CD009005-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 17 Mental state: 2. Specific ‐ b. positive symptoms ‐ iii. average score (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 18 Mental state: 2. Specific ‐ b. positive symptoms ‐ iv. change data (BPRS scale, high = bad)." data-id="CD009005-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 18 Mental state: 2. Specific ‐ b. positive symptoms ‐ iv. change data (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 19 Mental state: 2. Specific ‐ b. positive symptoms ‐ v. average score (SAPS scale, high = bad)." data-id="CD009005-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 19 Mental state: 2. Specific ‐ b. positive symptoms ‐ v. average score (SAPS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 20 Mental state: 2. Specific ‐ b. positive symptoms ‐ vi. change score (SAPS scale, high = bad)." data-id="CD009005-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 20 Mental state: 2. Specific ‐ b. positive symptoms ‐ vi. change score (SAPS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 21 Mental state: 3. Specific ‐ a. negative symptoms ‐ no clinical improvement." data-id="CD009005-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 21 Mental state: 3. Specific ‐ a. negative symptoms ‐ no clinical improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 22 Mental state: 3. Specific ‐ b. negative symptoms ‐ i. average score (PANSS scale, high = bad)." data-id="CD009005-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 22 Mental state: 3. Specific ‐ b. negative symptoms ‐ i. average score (PANSS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 23 Mental state: 3. Specific ‐ b. negative symptoms ‐ ii. change score (PANSS scale, high = bad)." data-id="CD009005-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 23 Mental state: 3. Specific ‐ b. negative symptoms ‐ ii. change score (PANSS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 24 Mental state: 3. Specific ‐ b. negative symptoms ‐ iii. average score (BPRS scale, high = bad)." data-id="CD009005-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 24 Mental state: 3. Specific ‐ b. negative symptoms ‐ iii. average score (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 25 Mental state: 3. Specific ‐ b. negative symptoms ‐ iv. change score (BPRS scale, high = bad)." data-id="CD009005-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 25 Mental state: 3. Specific ‐ b. negative symptoms ‐ iv. change score (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 26 Mental state: 3. Specific ‐ b. negative symptoms ‐ v. average score (SANS scale, high = bad)." data-id="CD009005-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 26 Mental state: 3. Specific ‐ b. negative symptoms ‐ v. average score (SANS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 27 Mental state: 3. Specific ‐ b. negative symptoms ‐ vi. average score (SANS scale, high = bad)." data-id="CD009005-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 27 Mental state: 3. Specific ‐ b. negative symptoms ‐ vi. average score (SANS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 28 Mental state: 4. Specific ‐ aggression/agitation ‐ average score (BPRS scale, high = bad)." data-id="CD009005-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 28 Mental state: 4. Specific ‐ aggression/agitation ‐ average score (BPRS scale, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 29 Adverse events: 1. General ‐ a. serious event or requiring discontinuation." data-id="CD009005-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 29 Adverse events: 1. General ‐ a. serious event or requiring discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 30 Adverse events: 1. General ‐ b. death (suicide or non‐suicide deaths)." data-id="CD009005-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 30 Adverse events: 1. General ‐ b. death (suicide or non‐suicide deaths). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 31 Adverse events: 2. Movement disorders ‐ a. any." data-id="CD009005-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 31 Adverse events: 2. Movement disorders ‐ a. any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 32 Adverse events: 2. Movement disorders ‐ b.i. average scores (SAS, high = bad)." data-id="CD009005-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 32 Adverse events: 2. Movement disorders ‐ b.i. average scores (SAS, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 33 Adverse events: 2. Movement disorders ‐ b.ii. change scores (SAS, high = bad)." data-id="CD009005-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 33 Adverse events: 2. Movement disorders ‐ b.ii. change scores (SAS, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 34 Adverse events: 2. Movement disorders ‐ b.iii. average scores (TESS, high = bad)." data-id="CD009005-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 34 Adverse events: 2. Movement disorders ‐ b.iii. average scores (TESS, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 35 Adverse events: 2. Movement disorders ‐ b.iv. average scores (DIEPSS, high = bad)." data-id="CD009005-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 35 Adverse events: 2. Movement disorders ‐ b.iv. average scores (DIEPSS, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 36 Adverse events: 2. Movement disorders ‐ b.v. change scores (BAS, high = bad)." data-id="CD009005-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 36 Adverse events: 2. Movement disorders ‐ b.v. change scores (BAS, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 37 Adverse events: 2. Movement disorders ‐ b.vi. change scores (AIMS, high = bad)." data-id="CD009005-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 37 Adverse events: 2. Movement disorders ‐ b.vi. change scores (AIMS, high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 38 Adverse events: 3. Endocrine ‐ prolactin level (high = bad)." data-id="CD009005-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 38 Adverse events: 3. Endocrine ‐ prolactin level (high = bad). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 39 Adverse events: 4. Metabolic ‐ a. weight gain (binary)." data-id="CD009005-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 39 Adverse events: 4. Metabolic ‐ a. weight gain (binary). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 40 Adverse events: 4. Metabolic ‐ b. average weight gain (kg)." data-id="CD009005-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 40 Adverse events: 4. Metabolic ‐ b. average weight gain (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 41 Adverse events: 5. Blood ‐ a. decreased white cell counts (binary)." data-id="CD009005-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 41 Adverse events: 5. Blood ‐ a. decreased white cell counts (binary). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 42 Adverse events: 5. Blood ‐ b. average white cell counts (10‐3/mm3)." data-id="CD009005-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 42 Adverse events: 5. Blood ‐ b. average white cell counts (10<sup>‐3</sup>/mm<sup>3</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 43 Adverse events: 6. Central nervous system (CNS) ‐ a. drowsiness." data-id="CD009005-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 43 Adverse events: 6. Central nervous system (CNS) ‐ a. drowsiness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 44 Adverse events: 6. Central nervous system (CNS) ‐ b. tremor." data-id="CD009005-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 44 Adverse events: 6. Central nervous system (CNS) ‐ b. tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 45 Quality of life: 1a. Average score (QLS high=good)." data-id="CD009005-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 45 Quality of life: 1a. Average score (QLS high=good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 46 Quality of life: 1b. Average score (SWN, high=good)." data-id="CD009005-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 46 Quality of life: 1b. Average score (SWN, high=good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 47 Quality of Life: 1c. Average score ‐ Mental component summary (SF‐36, high = good)." data-id="CD009005-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 47 Quality of Life: 1c. Average score ‐ Mental component summary (SF‐36, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 48 Quality of Life: 1d. Average score ‐ Physical component summary (SF‐36, high = good)." data-id="CD009005-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 48 Quality of Life: 1d. Average score ‐ Physical component summary (SF‐36, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 49 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Patients enrolled in the studies." data-id="CD009005-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 49 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Patients enrolled in the studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 50 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Treatment duration." data-id="CD009005-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 50 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 51 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Use of clozapine in both groups." data-id="CD009005-fig-0054" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 51 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Use of clozapine in both groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 52 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Drug added to clozapine." data-id="CD009005-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 52 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Drug added to clozapine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 53 SUBGROUP ANALYSIS Leaving the study early ‐ Patients enrolled in the studies." data-id="CD009005-fig-0056" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 53 SUBGROUP ANALYSIS Leaving the study early ‐ Patients enrolled in the studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 54 SUBGROUP ANALYSIS Leaving the study early ‐ Treatment duration." data-id="CD009005-fig-0057" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 54 SUBGROUP ANALYSIS Leaving the study early ‐ Treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 55 SUBGROUP ANALYSIS Leaving the study early ‐ Use of clozapine in both groups." data-id="CD009005-fig-0058" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 55 SUBGROUP ANALYSIS Leaving the study early ‐ Use of clozapine in both groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 56 SUBGROUP ANALYSIS Leaving the study early ‐ Drug added to clozapine." data-id="CD009005-fig-0059" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 56 SUBGROUP ANALYSIS Leaving the study early ‐ Drug added to clozapine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 57 SENSITIVITY ANALYSIS Clinical Response: Not clinically improved ‐ Randomisation." data-id="CD009005-fig-0060" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 57 SENSITIVITY ANALYSIS Clinical Response: Not clinically improved ‐ Randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 58 SENSITIVITY ANALYSIS Clinical Response: Not clinically improved ‐ Double blind." data-id="CD009005-fig-0061" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 58 SENSITIVITY ANALYSIS Clinical Response: Not clinically improved ‐ Double blind. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 59 SENSITIVITY ANALYSIS Clinical response: 1. No clinically important response ‐ not improved ‐ Fixed effect." data-id="CD009005-fig-0062" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 59 SENSITIVITY ANALYSIS Clinical response: 1. No clinically important response ‐ not improved ‐ Fixed effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 60 SENSITIVITY ANALYSIS Leaving the study early ‐ Randomisation." data-id="CD009005-fig-0063" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 60 SENSITIVITY ANALYSIS Leaving the study early ‐ Randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 61 SENSITIVITY ANALYSIS Leaving the study early ‐ Double blind." data-id="CD009005-fig-0064" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 61 SENSITIVITY ANALYSIS Leaving the study early ‐ Double blind. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009005-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/urn:x-wiley:14651858:media:CD009005:CD009005-CMP-001-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_t/tCD009005-CMP-001-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 62 SENSITIVITY ANALYSIS Leving the study early ‐ Fixed effect." data-id="CD009005-fig-0065" src="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.62</div> <div class="figure-caption"> <p>Comparison 1 ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY, Outcome 62 SENSITIVITY ANALYSIS Leving the study early ‐ Fixed effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/media/CDSR/CD009005/image_n/nCD009005-CMP-001-62.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD009005-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation</b> : randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> <b>Blindness</b> : double ‐ described and tested.<br/> <b>Duration</b>: 12 months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diagnosis:</b> schizophrenia (operational criteria).<br/> <b>N</b> = 600. *<br/> <b>Age:</b> any.<br/> <b>Gender:</b> both.<br/> <b>History:</b> any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Antipsychotic combination. N = 300.<br/> 2. Antipsychotic of choice. N = 300. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD009005-list-0004"> <li> <p>Global impression: CGI**, relapse, clinical improvement.</p> </li> <li> <p>Leaving study early (any reason, adverse events, inefficacy).</p> </li> <li> <p>Service outcomes: hospitalised, time in hospital, attending out patient clinics.</p> </li> <li> <p>Adverse events: major and minor problems as perceived by participant and clinician.</p> </li> <li> <p>Employment, family satisfaction, patient satisfaction.</p> </li> <li> <p>Quality of life: simple binary rating.</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> ** Primary outcome. </p> <p>CGI ‐ Clinical Global Impression.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009005-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combinations of antipsychotic drugs compared to single antipsychotic drugs for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Combinations of antipsychotic drugs compared to single antipsychotic drugs for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> schizophrenia or related disorders<br/> <b>Setting:</b> outpatients and inpatients<br/> <b>Intervention:</b> combinations of antipsychotic drugs<br/> <b>Comparison:</b> single antipsychotic drugs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single antipsychotic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with combinations of antipsychotic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response: No clinically important response</p> <p>‐ as defined by each of the studies<br/> follow up: range 4 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/> (0.64 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2398<br/> (29 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>512 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>374 per 1,000<br/> (328 to 425) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Relapse ‐ as defined by each of the studies<br/> follow up: range 2 months to 36 </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>512<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Data were not pooled due to high heterogeneity (I<sup>2</sup> = 82%). Two studies showed no difference between the interventions and one study favoured antipsychotic combinations. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leaving the study early<br/> follow up: range 6 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.76 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3137<br/> (43 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 5 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1,000<br/> (139 to 195) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service utilisation: Hospital admission<br/> follow up: range 12 weeks to 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.36 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>202<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1,000<br/> (25 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service utilisation: Change in hospital status ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No studies provided data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: Serious event or requiring discontinuation<br/> follow up: range 6 weeks to 8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.65 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2398<br/> (30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 5 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1,000<br/> (31 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: QLS, SWN and SF‐36<br/> follow up: range 6 weeks to 16 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were not pooled, as they were presented in both change and endpoint data for 3 different scales. None of the scales showed a difference between the two groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias. </p> <p><sup>2</sup> Downgraded one level due to inconsistency. </p> <p><sup>3</sup> Although there is a concern about the timeframe to measure the outcome we decided not to downgrade due to overall quality assessment. </p> <p><sup>4</sup> Downgraded one level due to publication bias. </p> <p><sup>5</sup> Downgraded one level due to imprecision. </p> <p><sup>6</sup> Downgraded one level due to indirectness. </p> <p><sup>7</sup> Although there is a concern about the influence on industry we decided not to downgrade due to overall quality assessment. </p> <p><sup>8</sup> Downgraded two levels due to inconsistency. </p> <p>Please see Checklist to aid consistency and reproducibility of GRADE assessments <a href="./appendices#CD009005-sec-0230">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combinations of antipsychotic drugs compared to single antipsychotic drugs for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009005-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐regression</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Estimate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>SE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Upper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐29.5401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.5608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐81.5983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.5181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2661</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.0114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2706</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chinese</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.7592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120.7041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐171.8166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301.3349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5916</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year*Chinese (interaction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.0326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.1508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5895</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>tau² (estimated amount of residual heterogeneity): 0.8884 (SE = 0.4106)</p> <p>tau (square root of estimated tau² value): 0.9426</p> <p>I² (residual heterogeneity / unaccounted variability): 97.91%</p> <p>H² (unaccounted variability / sampling variability): 47.80%</p> <p>R² (amount of heterogeneity accounted for): 0.00%</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐regression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/full#CD009005-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009005-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical response: 1. No clinically important response ‐ not improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.53, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.49, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical response: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.31, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.16, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.88, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.83, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 any antipsychotics in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.30, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Service utilisation: Hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.36, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.31, 26.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 any antipsychotics in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.25, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical response: 3. Global state ‐ i. average severity score (CGI‐S scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.31, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.55, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.37, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.42, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical response: 3. Global state ‐ ii. change in severity score (CGI‐S scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.09, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.09, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.24, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical response: 4. Global state ‐ average improvement score (CGI‐I scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.58, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.56, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.34, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical response: 5. Global state ‐ i. average functioning score (GAF scale, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.5 [‐8.38, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.73 [1.56, 15.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical response: 5. Global state ‐ ii. change in functioning score (GAF scale, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐1.42, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐1.56, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐4.21, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 1. Overall ‐ a.i average total score (PANSS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Any antipsychotic in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 1. Overall ‐ a.ii change in total score (PANSS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐3.42, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐3.54, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.26 [‐6.71, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 1. Overall ‐ b.i. average total score (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.15 [‐6.17, ‐2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.19 [‐7.08, ‐3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.09 [‐13.26, 7.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐1.36, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state: 1. Overall ‐ b.ii change total score (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.72 [‐5.37, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.72 [‐5.37, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mental state: 2. Specific ‐ a. positive symptoms ‐ no clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Mental state: 2. Specific ‐ b. positive symptoms ‐ i. average score (PANSS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.90, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.92, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 any antipsychotics in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐1.03, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Mental state: 2. Specific ‐ b. positive symptoms ‐ ii. change score (PANSS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.45, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.08, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.28, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Mental state: 2. Specific ‐ b. positive symptoms ‐ iii. average score (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐2.42, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.66 [‐3.32, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐1.61, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Mental state: 2. Specific ‐ b. positive symptoms ‐ iv. change data (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.16, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.16, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Mental state: 2. Specific ‐ b. positive symptoms ‐ v. average score (SAPS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.76 [‐11.91, ‐1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.76 [‐11.91, ‐1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Mental state: 2. Specific ‐ b. positive symptoms ‐ vi. change score (SAPS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐11.33, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐11.33, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Mental state: 3. Specific ‐ a. negative symptoms ‐ no clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Mental state: 3. Specific ‐ b. negative symptoms ‐ i. average score (PANSS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [‐0.49, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐1.18, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐1.51, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Any antipsychotic in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [1.60, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Mental state: 3. Specific ‐ b. negative symptoms ‐ ii. change score (PANSS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.54, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐1.11, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.69, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Mental state: 3. Specific ‐ b. negative symptoms ‐ iii. average score (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐12.25, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.69, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Mental state: 3. Specific ‐ b. negative symptoms ‐ iv. change score (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [‐0.29, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Mental state: 3. Specific ‐ b. negative symptoms ‐ v. average score (SANS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Mental state: 3. Specific ‐ b. negative symptoms ‐ vi. average score (SANS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐12.65, ‐0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐12.65, ‐0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Mental state: 4. Specific ‐ aggression/agitation ‐ average score (BPRS scale, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.3 [‐2.32, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events: 1. General ‐ a. serious event or requiring discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.65, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.82, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.37, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.09, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 any antipsychotics in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.79, 10.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events: 1. General ‐ b. death (suicide or non‐suicide deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse events: 2. Movement disorders ‐ a. any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.69, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.82, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 any antipsychotics in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.60, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Adverse events: 2. Movement disorders ‐ b.i. average scores (SAS, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Adverse events: 2. Movement disorders ‐ b.ii. change scores (SAS, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Adverse events: 2. Movement disorders ‐ b.iii. average scores (TESS, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Adverse events: 2. Movement disorders ‐ b.iv. average scores (DIEPSS, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.49, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.49, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Adverse events: 2. Movement disorders ‐ b.v. change scores (BAS, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐1.54, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐1.54, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Adverse events: 2. Movement disorders ‐ b.vi. change scores (AIMS, high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.84, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Other antipsychotic in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.84, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Adverse events: 3. Endocrine ‐ prolactin level (high = bad) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Adverse events: 4. Metabolic ‐ a. weight gain (binary) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.66, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.34, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.89, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Adverse events: 4. Metabolic ‐ b. average weight gain (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Adverse events: 5. Blood ‐ a. decreased white cell counts (binary) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Adverse events: 5. Blood ‐ b. average white cell counts (10<sup>‐3</sup>/mm<sup>3</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐0.20, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Adverse events: 6. Central nervous system (CNS) ‐ a. drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Adverse events: 6. Central nervous system (CNS) ‐ b. tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.47, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.12, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 Other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.47, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Quality of life: 1a. Average score (QLS high=good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐5.44, 7.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐5.44, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Quality of life: 1b. Average score (SWN, high=good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [‐1.08, 5.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [‐1.08, 5.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Quality of Life: 1c. Average score ‐ Mental component summary (SF‐36, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐4.28, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 Other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐4.28, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Quality of Life: 1d. Average score ‐ Physical component summary (SF‐36, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐4.71, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 Other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐4.71, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Patients enrolled in the studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 Chronic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.63, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 ≤12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.66, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 &gt;12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.51, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Use of clozapine in both groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.53, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2 other antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 SUBGROUP ANALYSIS Clinical Response: Not clinically improved ‐ Drug added to clozapine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.53, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 Sulpirirde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.43, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.3 Pipotazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.34, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 SUBGROUP ANALYSIS Leaving the study early ‐ Patients enrolled in the studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.74, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1 Chronic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.53, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 SUBGROUP ANALYSIS Leaving the study early ‐ Treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 ≤12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2 &gt;12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.66, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 SUBGROUP ANALYSIS Leaving the study early ‐ Use of clozapine in both groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.85, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2 Other antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.66, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 SUBGROUP ANALYSIS Leaving the study early ‐ Drug added to clozapine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.82, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1 Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.66, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2 Amisulpiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.06, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.3 Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.78, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.4 Pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.18, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.5 Sertindole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.38, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.6 Sulpiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 SENSITIVITY ANALYSIS Clinical Response: Not clinically improved ‐ Randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.1 Low / unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.66, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2 High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.27, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 SENSITIVITY ANALYSIS Clinical Response: Not clinically improved ‐ Double blind <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.1 Low / unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.62, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2 High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 SENSITIVITY ANALYSIS Clinical response: 1. No clinically important response ‐ not improved ‐ Fixed effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.68, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.56, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.2 other atypical in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.59, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 SENSITIVITY ANALYSIS Leaving the study early ‐ Randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1 Low / unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.2 High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 SENSITIVITY ANALYSIS Leaving the study early ‐ Double blind <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1 Low / unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.2 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.33, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 SENSITIVITY ANALYSIS Leving the study early ‐ Fixed effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1 clozapine in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.92, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2 other atypical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.3 typical drugs in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.53, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.4 any antipsychotics in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ANTIPSYCHOTIC COMBINATIONS vs ANTIPSYCHOTIC MONOTHERAPY</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009005.pub2/references#CD009005-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009005.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009005-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009005-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009005-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009005-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009005-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009005-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009005\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009005\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009005\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009005\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009005.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009005.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009005.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009005.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009005.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714050562"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009005.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714050566"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009005.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d653798ee937d',t:'MTc0MDcxNDA1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 